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Abstract
Development of Catalytic RNAs
as Potential Anti-HIV-1 Agents
by Pairoj Sae Chang

RNA molecules with enzymatic activity (ribozymes)
targeted to the genome of HIV-1 were developed and demon
strated to mediate site-specific cleavage of the HIV-1 RNA
in vitro and to inhibit viral proliferation intracellularly.
Two classes of ribozymes that incorporate a "hammerhead"
catalytic center were utilized,

The first class used nucl-

eotide elements in the viral sequence to provide half of the
catalytic center.

A complementary strand harboring the

remaining active site nucleotides was supplied in trans and
directed the site-specific cleavage of the HIV-1 RNA target.
A second type of ribozyme incorporated the entire catalytic
center, minus the site of cleavage, within a single RNA
molecule.

Ribozymes of this design were targeted to two

different sites in the HIV-1 gag gene and a single site in
the viral 5* LTR region.

Efficient catalysis of each target

was obtained at a physiological temperature.

One of the

ribozymes was expressed in CD4+ HeLa cells and was shown to
be functionally active against an HIV-1 gag RNA target in a
cell-free assay.

When challenged with HIV-1, the CD4+ HeLa

cells expressing the ribozyme produced 10-fold less gag-p24
antigen compared to CD4+ Hela parental cells.

Polymerase

chain reaction analysis of the total RNA from infected cells
supported the hypothesis that ribozymes mediated the sitespecific cleavage of HIV-1 RNAs intracellularly, resulting
in lowered susceptibility to HIV-1 infection.
The possibility of delivering preformed ribozymes into
the cells was also explored.

Preliminary data suggests that

a sufficient quantity of preformed ribozymes was taken up by
H9 lymphocytes to render them more resistant to HIV-1 infec
tion than control cells.

The amount of delivered, preformed

ribozyme can be increased by a lipid-delivery system (liposome).

Experiments utilizing a liposome delivery system

into human H9 lymphocytes are described.
Finally, this study describes the use of the yeast Saccharomvces cerevisiae as a eukaryotic model for studying
ribozyme expression and function,

Several ribozyme express-

ing constructs have been transformed into yeast, setting the
stage for future studies in this organism.
Catalytic RNAs such as those described in this thesis
should prove to be effective therapeutic agents against HIV1.
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INTRODUCTION

AIDS and HIV-1 infection
Acquired Immune Deficiency Syndrome (AIDS) is a slow
degenerative disease of the immune and central nervous
systems (Fauci et. al., 1984; Price et. al., 1988).

This

complex syndrome usually starts with immunologic dysfunction
that enables normally benign organisms to flourish destruc
tively in the affected individual. AIDS is also associated
with malignant neoplastic disease transformation (Kaposi's
sarcoma)

(Marmor et al., 1984? Friedman-Kien et al., 1982)

and in late stages, neurologic degradation (AIDS dementia)
(Navia et al., 1986? Price et. al., 1988). The syndrome was
first described in 1981 as a mysterious complex of rare
diseases that had become common in homosexual men at an
alarming rate (Gottlieb et al., 1981; Masur et al., 1981).
Its etiologic agent, a retrovirus, the human immunodeficien
cy virus type I (HIV-1), was not identified until 1984
(Barre-Sinoussi et al., 1983? Popovic et al., 1984? Levy et
al., 1984). Since then the focus has slowly and rightfully
shifted from treating the symptoms to control of the viral
infection and the understanding of the virus itself.
HIV-1 shares in vitro characteristics, nucleotide
sequences, and morphologic properties with a sub-group of
the nontransforming, cytopathic, lentivirus family of retro
viruses (Gonda et al., 1985? Sonigo et al., 1985? Stephens
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et al., 1986; Chiu et al., 1985). The lentiviruses with
similarity to HIV-1 are 1) visna virus, capable of causing
chronic neuro-degenerative diseases in sheep (Nathanson et
al., 1985; Narayan and Cork, 1985) and 2) equine infectious
anemia virus, capable of inducing episodic fevers and hemo
lytic anemia in horses (Cheevers and McGuire, 1985). Recent
ly, a new group of lentiviruses has been isolated from
different species of monkeys, termed simian immunodeficiency
viruses (SIV)

(Daniel et al., 1985; Murphey-Corb et al.,

1986; Tsujimoto et al, 1989). Sera from animals infected
with SIV isolated from chimpanzees (SIVCpz) was shown to
cross react with all the HIV-1 proteins (Peeter et al..
1989) . SIVCPZ contains 80% sequence homology with HIV-1 and
is the only retrovirus that has all the genetic composition
and organization similar to HIV-1 (Huet et al., 1990).
HIV-1 has at least nine genes, which can be divided
into two groups; 1) those that encode the proteins found in
the virus particle, the virion structural proteins; and 2)
those that encode the proteins that regulate viral replica
tion (Gallo, 1987; Haseltine and Wong-Staal, 1988). All of
the viral structural proteins are specified by only three
genes gag, pol. and env. The other six gene products, for
two of which the functions are unknown, interact to regulate
the expression of the three structural genes and to maintain
viral homeostasis. Gag encodes four proteins pl7, p24, p9
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and p7 which are derived from a single precursor protein of
55 kDa size (Bolognesi, 1988). The peptide p24 is the major
core protein which self-aggregates into a bullet shaped
capsule surrounding two copies of the viral RNA genome, and
two copies of all the non-regulatory enzymes to form a viral
particle (Canaani et. al., 1973; Chider et. al., 1980).

The

mRNA that encodes the gag proteins is a large unspliced mRNA
containing the whole genome (Fig. 1). All of the non-regulatory enzymes are encoded by the single-copy pol gene which
is translated into a large precursor gag-pol fusion protein
of 190 kDa. This protein undergoes proteolytic processing
via its own protease, generating four enzymes, the RNAdependent DNA polymerase known as reverse transcriptase,
ribonuclease H, integrase and protease. This large gag-pol
fusion protein is the result of translation of the full
length mRNA initiated at the same AUG as the gag protein
alone. Translation of this message then undergoes a reading
frame-shift between the junction of the gag coding sequence
and the pol coding sequence (Fig. 1). The frequency of this
ribosomal frame shift transition is about 1 in every 20
translations (Jacks et. al., 1987; Wilson et. al., 1988).
The last structural gene is env. which gives rise to an
envelope glycoprotein complex of two components, the larger
outer domain, gpl20, and the transmembrane domain gp41
(Robey et. al., 1985; Allan et. al., 1985). The mRNA for the

A

Figure 1. Schematic of HIV-1 mRNAs•
All HIV-1 mRNAs contain the transactivator responsive (TAR) sequences at their 5'
ends and polyadenylation at their 3' ends. Only mRNAs that encode structural proteins
contain the two cis-acting sequences, cis-acting repressive sequence (CRS) and revresponsive (RRE) sequence. The two cis-acting sequences are spliced out of mRNAs that
encode for the regulatory proteins by the different splice donor (SD) and splice
acceptor (SA) sites. The numbers represent the length of the viral genome in kilobase
and "fs" stands for reading frame shift of ribosome.
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env gene is subjected to a single splicing event which
removes the gag and pol coding sequences (Fig. 1).
To regulate the expression of the three viral component
genes, an intricate system of regulation involving an addi
tional repertoire of three proteins has been proposed
(Gallo, 1987; Haseltine and Wong-Staal, 1988). Functional
expression of all of the non-structural genes requires
splicing of the full length viral RNA (Fig. 1). A transact
ivator protein, tat, stimulates the expression of all the
viral mRNAs containing the transactivator responsive region,
TAR (Rosen et al., 1986). TAR is a sequence located at the
5' end of all viral mRNAs (between the first and 40th nucle
otides of the viral transcribed region), which is required
for tat to function (Rosen et al., 1986; Cullen, 1986;
Wright et al., 1986; Peterlin et al., 1986). TAR itself is a
cis-acting negative regulator of transcription,

In the

absence of tat, transcription of TAR-initiated mRNA is
unstable and only the initial 50 nucleotide segment accumu
lates, due to the premature termination of the RNA poly
merase II elongation reaction (Kao et al., 1987).
A second regulatory protein rev, or regulator of
virion-protein expression, has two different effects on
viral regulation 1) an antirepressor of translation (Sodroski et al., 1986) and 2) a trans-regulator of splicing
(Feinberg et al., 1986) . Rev requires two types of
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cis-acting sequences for its functions, the multiple cisacting repressive sequences (CRS) located only in the three
structural genes and the single cis-acting rev-responsive
region (RRE) sequence located in the envelope gene (Fig. 1).
If the CRS sequences are present on the mRNA molecule, that
RNA molecule will be translated efficiently only in the
presence of a rev product, otherwise, CRS sequences act as
an inhibitor of translation. The RRE sequence responds to
rev, preserving the structural gene sequences and inhibiting
the regulatory gene sequences from splicing out of the
transcript. Since only the mRNA for the viral structural
proteins contain the two cis-acting sequences (Fig. 1), the
expression of rev enables the virus to selectively produce
the structural proteins.

(Feinberg et al. 1986). The inter

relationship of tat and rev regulation starts with the
stimulatory effect of tat protein on the TAR sequence re
sulting in the indiscriminate, increased production of all
the viral transcripts. The next level of control is via the
rev protein. The presence of rev increases the cytoplasmic
concentration of the RRE containing mRNA. These mRNAs also
contain CRS sequences which are being de-repressed, leading
to higher production of the viral component proteins. When
the concentration of rev protein is low, viral protein
synthesis is mainly dedicated to the production of more
regulatory proteins, including rev. These feedback loops of

8
control are a way of insuring adequate levels of viral
replication, and hence viral survival (Gallo, 1987).
The third regulatory gene encodes a 27 kDa protein
called the negative regulatory factor (nef)

(Allan et al.,

1985). The high level of nef expression slows down the
transcription of all viral RNAs, including that of nef
itself (Ahmad and Venkatesan, 1988; Luciw et al., 1987).
This inhibitory effect requires a cis-actinq region 5' to
the enhancer sequences called the negative regulatory element (NRE)

(Rosen et al., 1985).

The nef protein is myris-

tylated at the amino terminus, and accumulates in the cytoplasm (Alan et al., 1985).

The characterization of purified

nef protein demonstrates that nef binds to GTP and has a
GTPase activity (Guy et al., 1987).

It is also a protein

kinase capable of autophosphorylation, and is itself a
substrate for protein kinase C (Guy et al., 1987).

The

exact mechanism by which nef regulates viral transcription
is unclear, although it has been proposed that nef inhibits
viral transcription by modifying a cellular protein which
interacts with NRE sequences leading to down regulation of
viral transcription (Guy et al., 1987).
The main functions of rev, tat and nef are to maintain
a homeostasis between the selective expression of the regu
latory proteins and viral structural proteins, leading to
modest replication of the virus at a level sustainable by
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the host cells.
Three other genes that have been identified are vif
(Rabson and Martin, 1985; Ratner et al., 1985), vpu (Cohen
et al., 1988; Strebel et al., 1988) and vor (Wong-Staal et
al., 1987). Only the vif gene, virion infectivity factor,
has been somewhat characterized. The vif gene encodes a
small protein that accumulates in the cytoplasm of infected
cells and is also found extracellularly. The vif protein may
facilitate viral entry into the cell by free virus after
attachment to the cell membrane, as determined by the lower
infectivity of virions lacking a functional vif gene. How
ever, cell to cell transmission of vif-negative virus is
normal (Strebel et al., 1987).
The immunologic pathogenesis of AIDS has been at
tributed mainly to the reduction in, and loss of function of
a specific set of white blood cells called T4 lymphocytes,
also known as helper T cells (Fauci et al., 1985; Bowen

et

al., 1985). The reduction, mainly of helper T cells, is due
to the selective binding of HIV-1 via its surface glyco
protein gpl20 to the CD4 surface receptor (Dalgleish et al.,
1984; Klatzmann et al., 1984a; McDougal et al., 1986). This
selective binding event results in HIV-1 infection only of
cells containing CD4 surface receptors (Klatzmann et al..
1984b; Maddon et al., 1986).

One of the main reasons for

the immune dysfunction is the depletion of the population of
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the helper T cells below a critical level, thus interfering
with the normal function of T4 lymphocytes (Gottlieb et al.,
1981; Bowen et al., 1985). Besides reducing the T4 lym
phocyte population, the viral infection also directly af
fects the function of the helper T cells, resulting in

1)

decreased blast transformation to antigens, 2) decreased
lymphokine production, 3) decreased allo-reactivity, 4)
diminished cytotoxic cell response and 5) depressed helper
function for B-cell-immunoglobulin production (Bowen et al.,
1985).
The main pathological manifestation of HIV-1 infection
is the depletion of the helper T-cell population (Gottlieb
et. al., 1981; Bowen et. al., 1985). The exact mechanisms of
cell-killing are not fully understood since only a small
fraction of T4 cells in the body are actually infected.
Several mechanisms of killing have been documented in the
laboratory, whether they also occur in the body is not yet
known. One mechanism is the formation of multi-nucleated
syncytia, which result from the fusion of cell membranes of
infected cells with uninfected cells. The fusions are
mediated by the high affinity binding of the viral gpl20
surface proteins of infected cells with the CD4 receptors of
the uninfected T4 cells. The final result of such fusions
are the creations of large, non-functional syncytia of T4
cells (Lifson et. al., 1986a,b,c; Yoffe et. al., 1987).
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Another possible mechanism of the T4 cell loss is the
killing of the infected T4 cells by cytotoxic T cells as
well as antibody mediated destruction. The same process can
also occur with uninfected cells that have the free gpl20
bound to their CD4 receptors, mimicking infected cells. The
binding of the gpl20 may thus mark the uninfected cells for
destruction by the immune system (Klatzmann and Gluckman,
1986).
Other possible mechanisms are: 1) changes in the HLA
class II phenotypes of the infected cells making them sus
ceptible to immune destruction (Sattentau et. al., 1986); 2)
the increased susceptibility of infected cells to superin
fection by other pathogens such as cytomegalovirus (Schrier
et. al., 1985; Cann et. al., 1985; Gendelman et. al..
1986a);

3) accumulation of unintegrated HIV-1 DNA (Weller

et. al., 1980; Keshet et. al., 1979); and 4) triggering of
T4 helper cells to begin terminal differentiation leading to
pre-mature death (Zagury et. al., 1986).

The final

immunological outcome of the infection is the increased
susceptibility of the infected individual to opportunistic
infections, mainly those that are normally defended by cell
mediated immunity, such as viral, fungal, parasitic and
certain bacterial infections (Bowen et. al., 1985).
In addition to the immune dysfunction, HIV-1 also
causes neurologic dysfunction, clinically characterized by
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poor memory, inability to concentrate, apathy and psycho
motor retardation (Navia et al., 1986a? Snider et. al.,
1983; de la Monte et. al., 1987). The predominantly infected
cell types in the brain are monocytes and macrophages
(Gabuzda et al., 1986; Koenig et al., 1986; Navia et. al.,
1986b). Cerebral endothelial cells have been demonstrated to
contain the virus in only one study (Wiley et al., 1986).
Based on these findings and the known patho-genic mechanisms
of lentiviral infections (Haase, 1986? Gendelman et al.,
1986b), two pathogenic schemes are proposed. In the first,
HIV-1 infects the monocyte peripherally, which then enters
the brain carrying the virus across the blood-brain barrier.
With the cellular activation, HIV-1 replicates in the mono
cytes and macrophages causing them to release monokines and
proteolytic enzymes that are toxic to neural cells. The
monocytes and macrophages can also release chemotactic
factors inducing further infiltration by inflammatory cells.
The neurons and glial cells are destroyed as "innocent-by
standers" (Price et al., 1988). The second scheme involves
the blood-brain barrier cells (cerebral endothelial cells)
which may cause abnormal permeability of the barrier as a
result of HIV-1 infections, resulting in neurologic dysfunc
tion (Wiley et al., 1986).
AIDS is a disease that begins with the single event of
HIV-1 infection and slowly progresses into multi-system
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dysfunction. The therapeutic strategies must ultimately
target the control of continuous viral replication and
spread (Haseltine 1989). Currently, the only antiviral drug,
azidothymidine or AZT, approved for inhibition of HIV-1
replication are immunosuppressive (Hirsch, 1990). One of the
goals in developing antiviral therapies is to develop viral
specific inhibitors which have minimal cytotoxic or immuno
suppressive side effects. One theory in development is the
use of antisense agents to inhibit specific viral genes.
Such disruption could occur by interrupting normal HIV-1
gene regulation or viral replication leading to specific
viral inhibition.
Antisense inhibition
The impairment of gene expression by complementary
Watson-Crick RNA-RNA or RNA-DNA duplex formation has been
termed "antisense" inhibition (Izant and Weintraub, 1984).
It was first shown that complementary sequences can function
to inhibit in vitro translation of mRNA, termed hybridarrest (Paterson et al., 1977; Hastie and Held, 1978).
Subsequent to these in vitro experiments, numerous artifi
cial antisense RNAs and synthetic oligo-DNAs have been
demonstrated to inhibit gene expression in vivo (reviewed in
van der Krol et al., 1988b)

Antisense regulatory mechanisms

occur naturally in at least 12 different systems in the form
of complementary RNAs. The first natural antisense was
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described in the bacterium, E. Coli. as a means for con
trolling plasmid replication and copy number of the ColEl
family of plasmids (Tomizawa, 1987). The regulation involves
binding of a 108 nucleotide long, antisense RNA (RNA I) to a
portion of the precursor of the replication primer RNA (RNA
II). Upon

the formation of this complex, RNA II is prevent

ed from hybridizing to the DNA origin of replication, thus
blocking its use as a primer for DNA replication. Main
tenance of copy number control and/or plasmid incompatibi
lity using an antisense intermediate has been described in
the

E. coli plasmid IncFll (Light and Molin 1983); the

Staphylococcus aureus plasmid pT181 (Kumar and Novick 1985);
and the broad host-range plasmid R1162 (Kim and Meyer,
1986). However, the exact modes of action are different in
all of the plasmid control mechanisms. The regulation of the
TnlO transposase expression by RNA-OUT (Simons and Keckner,
1983) , the autoregulation of cAMP-receptor protein synthesis
by

tic RNA (Okamoto and Freundlich, 1986), and osmoregula

tion of porin expression in E. coli by micF (Mizuno et al.,
1984) also involve genetically characterized antisense RNAs.
The lysis-lysogenic replicative cycle controls of phage p22
in Salmonella (Liao et al., 1987; Wu et al., 1987) and phage
lamda in E. coli (Hayes and Szybalski, 1973) have also been
shown to involve the participation of the small antisense
RNA transcripts, sar and

pop.
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The presence of antisense RNA is not limited to proka
ryotes. In eukaryotes, several naturally occurring antisense
transcripts have been identified (Nepveu and Marcu, 1986;
Spencer et al., 1986; Williams and Fried, 1986; Adelman et
al., 1987; Kindy et al., 1987; Lazar et al., 1989) but the
exact roles of these transcripts in gene regulation are not
known. Recently, the smallest of the three maternal basic
fibroblast growth factor (bFGF) transcripts from Xenoous
oocytes was shown to contain sequences complementary to the
largest transcript, which encodes the complete bFGF polypep
tide (Kimelman and Kirschner, 1989). The overlapping region
between the two transcripts is modified by the conversion of
half of the adenosine residues to inosine during oocyte
maturation. This type of modification was first described by
Bass and Weintraub (1987) for unwinding artificial doublestranded RNA duplexes in Xenopus oocytes. This covalent
modification of the bFGF mRNA has been proposed as a regula
tory mechanism for maintaining its stability (Kimelman and
Kirschner, 1989).
The use of synthetic oligo-deoxyribonucleotides as
inhibitors of viral infection was the first in vivo demonst
ration of antisense inhibition in a eukaryotic system.
Zamecnik and Stephenson (1978) used a synthetic tridecadeoxy-oligonucleotide (13mer) complementary to the 5' and 3'
reiterated terminal sequences of Rous sarcoma virus(RSV) to
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inhibit RSV replication in cultured chick EF cells. This
experiment clearly demonstrated that oligomers could be
taken up by cells and interfere with gene expression. With
the development of and increased availability of fast and
reliable techniques for the chemical synthesis of DNA, the
use of antisense oligomers and their analogs has been widely
employed for the transient inhibition of viral and cellular
gene expression in cultured cells (van der Krol et al..
1988b; Zon, 1988).
Due to the transient nature of oligo-DNA mediated
antisense inhibition, long term inhibition necessitated the
construction of artificial antisense genes for continued
expression in vivo. The antisense gene can be integrated
into the host genome resulting in long term expression of
antisense RNAs. The first functional in vivo expression of
an artificial antisense gene was described by Izant and
Weintraub (1984) using an antisense thymidine kinase (TK)
gene to block expression of Herpes simplex virus-TK gene in
cultured mouse cells. The intracellular expression of an
tisense genes has been shown to inhibit expression of both
endogenously expressed and exogenously supplied genes. These
include the following chloramphenicol acetyl transferase
(Harland and Weintraub, 1985; Ecker and Davis, 1986), 8actin genes (Izant and Weintraub, 1985), and proto-oncogenes
c-fos (Holt et al.,1986; Mercola et al., 1987; Nishikura and
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Murray, 1987), c-mvc (Yokoyama and Imanoto, 1987) and c-src
(Ammini et al, 1986]).
Antisense technology has advanced from inhibition
within single cell systems to multicellular organisms such
as the wingless mutants of Drosophila (Cabrera et al..
1987), the "shiverer" phenocopies of transgenic mice (Katsuki et al., 1988) and transgenic plants harboring the
anti-Aarobacterium gene (Rothstein et al. 1987), anti-chalcone synthase gene (van de Krol et al., 1988a), anti-polygalacturonase gene (Sheehy et al. 1988) and anti-tobacco
mosaic virus gene (Powell et al., 1989). One of the goals in
the use of antisense technologies is to ultimately be able
to transfer the technology out of the laboratory and into
agricultural or clinical settings for such processes as the
elimination of and replacement of undesirable cellular
proteins in plants, and/or the elimination of viral infec
tion in humans (Weintraub, 1990).
Before any applications of antisense technology can
occur, several problems with the technique have to be ad
dressed. With a few exceptions (Rubenstein et al., 1984;
Pestka et al.; 1984 ), one of the main problems is the
requirement for large excesses of antisense molecules rela
tive to the targeted substrate. Approximately 50-100 fold
excesses are often required (Izant and Weintraub, 1985;
Harland and Weintraub, 1985; Melton, 1985).

The lower
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stability of antisense RNA as compared to sense mRNAs may
contribute to this phenomenon (van der Krol et al., 1988b).
Another potential factor is the RNA duplex unwinding-modifi
cation activity found in a wide variety of cells (Wagner and
Nishikura, 1988)

. The unwinding is due to the deamination

of adenosine to inosine, forming less stable U:I base pair
ing, rendering the antisense and sense transcripts non
functional.

Antisense molecules, that contain endonuclease

activity are capable of cleaving multiple substrates and are
not substrates for unwinding modification activities, should
conceivably reduce the requirement for large concentrations
of antisense RNAs. Several groups of catalytic RNAs offer
promise for such a new class of anti-sense.
Catalytic RNAs or Ribozymes
The discoveries that certain RNA molecules have en
zymatic activity are among the most important recent find
ings in biology. These were first described in two different
systems; 1) the autocatalytic removal of the intervening
sequence from the large ribosomal RNA precursor of
Tetrahvmena thermoohila (Zaug and Cech, 1982, 1986; Zaug et
al., 1983) and 2) the processing of pre-tRNA in E. coli by
the Ml subunit of RNase P (Guerrier-Takada et al., 1983).
Subsequent to these initial findings, other catalytic RNAs
have been found in a number of systems from bacteria through
man (Cech, 1988, Cech and Bass, 1986). Some of the enzymatic
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activities described for RNA are polymerase activity (Zaug
and Cech, 1986), DNase activity (Herschlag and Cech, 1990),
and polysaccharide branching activity (Shvedova et al.
1987) .
Several infectious plant RNAs undergo efficient, autocatalytic site-specific cleavage in vivo.

Among these RNAs

are viroids, which are the small, self-replicating circular
RNA molecules of a few hundred nucleotides, and are pathoge
nic to certain flowering plants (Keese and Symons, 1987?
Riesner and Gross, 1985).

Viroids do not code for any

proteins, and require host factors for their replication.
Another class of self-cleaving RNAs are classified as virusoids, a subgroup of molecular parasites known as
RNAs (Francki et al., 1985).

satellite

These circular RNAs are

viroid-like in size and structure and undergo encapsulation
together with certain plant viruses. The virusoids do not
self-replicate, but behave as satellite RNAs of conventional
viruses, being dependent on a viral polymerase for replica
tion. The replication of both viroid and virusoids occur via
a rolling circle mechanism

(Forster and Symons, 1987a). The

genomic strand (plus strand) replicates from a circular
template yielding multimers which can either stay as such
(Fig. 2, step 3a) or self-cleave

into monomeric units of

the negative strand (Fig. 2, step 4b).

The self-cleaved

monomeric units can undergo intramolecular ligation (Fig. 2

to

o

Figure 2. Two hypothetical schemes for viroid and virusoid replication via rolling
circle mechanism.
The genomic circular (+) strand undergoes replication by rolling circle mechanism
(steps 1 and 2) to produce a multimeric complementary (-) strand. The multimeric (-)
strand can either be used directly as template for the production of multimeric (+)
strands (step 3a) or undergoes self-cleavage reactions (steps 3b and 4b) yielding
monomeric complementary (-) strands. The monomeric (-) strands are circularized by
plant ligase (step 5b). These circular monomer (-) strands are used as templates for
the production of multimeric ( + ) strands by rolling circle mechanism (steps 6b and 7b) .
The multimeric (+) strands (step 8) self-cleave to produce monomeric (+) RNAs (step
9) . The unit length RNAs circularize by plant ligase (step 10) to produce new progeny
circles.
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step 5b), presumably mediated by a plant RNA ligase, to form
monomeric circles (Keese and Symons, 1987; Riesner and
Gross, 1985). The replicative process repeats itself utiliz
ing either the uncleaved linear multimeric or the selfcleaved circular monomeric forms as templates for replica
tion of the genomic strand multimers, followed by self
cleaving and circularization of the cleavage products,

The

cleavages of both strands are site-specific, and generate
2'-3'cyclic phosphate and 5' hydroxyl termini (Forster et
al., 1987, 1988? Forster and Symons, 1987a,b; Prody, 1986).
The self-cleavage properties of viroids and virusoids are
mediated by the extensive secondary structures which fold
into the so called "hammerhead" configuration (Fig. 3)
(Forster and Symons, 1985).
The hammerhead model of RNA self-cleavage is not con
fined to the plant kingdom. The 330 bp tandemly repeated
satellite-2 transcripts from the newt, Notophthalmus viridescens, have been shown to have self-cleavage activity
mediated by a hammerhead configuration (Epstein and Gall,
1987) .
Beside the hammerhead model of self-cleavage RNA

found

in viroids, virusoids and satellite RNAs, the negative
strand of the linear satellite RNA of the tobacco ringspot
virus [(-)sTRSV]

(Hampel and Tritz, 1989) and a domain of

hepatitis delta virus (HDV), an important cofactor in

to
u>

Figure 3. Four models of trans-acting •'hammerhead11 ribozyme.
The ribonucleotides require for cleavage activity are depicted by their one letter
designations. N and N' or X and X' are any nucleotides that can form a Watson-crick
basepair. Each model depicted has one substrate strand, containing the cleavage site,
and at least one catalytic strand to complete the hammerhead structure.
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fulminant human hepatitis B infection, have also been shown
to autocleave in vitro (Sharmeen et al., 1988; Kuo et al.,
1988? Wu and Lai, 1989; Wu et al., 1989).

The sTRSV is not

considered a virusoid even though it exists in both circular
and linear forms, since only the linear form is encapsulated
by the virus. The catalytic domains of the [(-)sTRSV] have
subsequently been termed the "hairpin” model (Tritz and
Hampel, 1989). In the case of HDV, its structure (single
stranded, circular RNA) and its replication mode (rolling
circle) are very similar to the viroid's. However, the HDV
genome is considerly larger (1.7 kilobases) and is known to
encode at least one structural protein. Its catalytic do
main, a highly structured cruciform type conformation.
resides in a stretch of no more than 117 nucleotides around
the cleavage site .
Perhaps the simplest RNA auto-cleavage domain is the
catalytic center of the "hammerhead" group.

A high degree

of primary and secondary homology among the self-cleavage
sites of the "hammerhead" family of ribozymes

has been

demonstrated (Buzayan et al., 1986? Forster and Symons,
1987a? Hutchins et al., 1986? Prody et al., 1986).

Within

this structure are 13 conserved nucleotides which are
divided into three domains CUGANGA, GAAAC, and GUC, compris
ing the catalytic center (Fig. 3).

In nature, at least

three types of hammerhead catalytic centers have been
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demonstrated: 1) the virusoids of velvet tobacco mottle
virus, solanum nodiflorum mottle virus and subterranean
clover mottle virus (Forster and Symons, 1987a? Keese and
Symons, 1987) have the conserved nucleotides coming from a
relatively small contiguous region of the virusoid RNA; 2)
the plus and minus hammerheads of the avocado sunblotch
viroid draw their autocatalytic center from two regions
which are separated by a large number of nucleotides (Hut
chins et al., 1986); and 3) Forster et al.

(1988) proposed

that avocado sunblotch viroid and the newt satellite sequen
ces, which have potentially unstable conformations at the
auto-cleavage site, form dimerized "hammerhead" structures.
Forster and colleagues (1987) first demonstrated for
the avocado sunblotch viroid that the essential constituents
for the hammerhead could be brought together in trans. with
one of the molecules serving as a catalyst (containing
CUGANGA domain with flanking antisense sequences) for the
cleavage of the substrate strand (containing the GAAAC
domain and the GUC cleavage site) under appropriate condi
tions of annealing, cleavage, dissociation, and reannealing
(Fig. 3, model I).

A similar trans-acting catalytic

cleavage has been demonstrated in a simple system composed
of two short, in vitro transcribed strands of RNA harboring
the 13 conserved nucleotides held together by base pairing
(Uhlenbeck, 1987? Sampson et al., 1987). A different design
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of hammerhead trans-acting ribozyme has also been
demonstrated by allowing two catalytic strands of 13 and 19
base long oligoribonucleotides to anneal with, and catalyze
the cleavage of an 11 base long substrate oligoribonucleotide (Fig. 3, model II)

(Koizumi et al., 1988). A

third design of hammerhead trans-acting ribozyme (Fig. 3
model III), utilizing information from the self-cleavage
domain of the lucerne transient streak virus, was demon
strated using a 13 base long oligoribonucleotide to catalyze
the cleavage of a 41 base long oligoribonucleotide (Jeffries
and Symons, 1989). In each case, the ribozyme cleavage takes
place at a specific site in the substrate, and turns over
greater than stoichiometric amounts of substrate.
A more generally useful trans-acting ribozyme
been described by Haseloff and Gerlach (1988).

has

They have

overcome the problem of bringing three separate nucleotide
elements into the proper catalytic conformation.

Utilizing

the hammerhead autocleavage domain found in the plus strand
of satellite RNA of tobacco ringspot virus, they designed a
set of trans-acting ribozymes targeted to the chloram
phenicol acetyltransferase (CAT) RNA. The trans-acting
catalytic strand harbors 11 out of the 13 required
nucleotides (Fig. 3, model IV), with only a GUN cleavage
domain (where N is A, C or U) being supplied by the target
strand.

The reduction of sequence requirement for substrate
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strand to only GUN cleavage domain as compared to the ear
lier three models, greatly expands the number of potential
targets for cleavage.

Using this approach, several dif

ferent sites within the CAT transcript were shown to be
susceptible to ribozyme cleavage in vitro.
Recently, Koizumi et al.

(1989) showed that a further

reduction in the number of essential bases, from 13 to 11
nucleotides, is possible. The conserved bases GAAAC and GUN
can be reduced to GAAAX! and X2UN, when X, and X2 nucleotides
can form a Watson-Crick base pair. This finding reduces the
requirement of the target site for the model IV trans-acting
ribozyme to any occurrence of the UC, UA or UU di
nucleotides. This reduction to the di-nucleotide cleavage
domain, greatly increases the possibilities of finding
targets within any RNA.
Trans-acting catalytic RNAs are potential anti-viral
therapeutic agents.

We have focused on the use of ribozymes

targeted against HIV-1 RNA as a potential anti-viral agent.
Based upon the plant viroid and virusoid models in which the
catalytic domains are composed of three groups of highly
conserved sequence elements, we have designed several trans
acting "hammerhead" model ribozymes targeted to HIV-1 RNAs.
These are based on two modes of cleavage, one in which part
of the catalytic center (GAAAC and GUC) is supplied by HIV-1
RNA sequences as in model I ribozyme, and the other; based
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upon the Haseloff and Gerlach design (model IV), in which
only a GUN is supplied by the HIV-1 RNA. In vitro, these
cleavage reactions are specific, multiple substrate turnover
is observed, and specific cleavage reactions can take place
in a milieux containing total cellular RNAs. The synthetic
catalytic RNAs, when taken up by human cells, render the
cells less susceptible to HIV-1 infection. We also
demonstrate that a biologically active ribozyme is expressed
in a cell culture system, and intracellularly expressed
anti-HIV-1 ribozyme renders the cells less susceptible to
HIV-1 infection. The reductions in excreted p24 viral
antigen, and viral gag mRNA from the ribozyme-expressing
cells are compatible with the hypothesis that the ribozyme
catalyzed cleavage of viral transcripts.

Most importantly,

these results point to the potential use of hammerhead
ribozymes as anti-HIV-1 therapeutic agents.
Studies have been initiated with the use of the yeast,
Saccharomvces cerevisiae. as a model system to optimize
ribozyme function intracellularly.

Yeast is one of the

simplest eukaryotic organism, yet it contains many of the
fundamental cellular properties of higher eukaryotes (such
as subcellular organelles, secretion systems, cytoskeletal
organization, receptor and second messenger arrangements,
metabolic regulation, RNA processing and chromosome
mechanics (Strathern et al., 1981; 1982) making it an ideal
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system for studying eukaryotic cellular and molecular
biology. Numerous mammalian regulatory proteins, such as
transcriptional factors (Chodosh et. al., 1988; 1989?
Harshman et al. 1988; Kakidani and Ptashne, 1988; Lambert
et. al., 1989; Struhl, 1987? Webster et al., 1988), ras
oncogene (Katoaka et al., 1985; DeFeo-Jones et al., 1985),
and steroid receptors (Metzger et. al., 1988; Schena and
Yamamoto, 1988) have been shown to function in yeast and
some, vice versa. Comparisons of the amino acid sequences of
proteins from yeasts and mammals have identified several
highly conserved structural protein (Botstein and Fink,
1988). The many similarities in cellular characteristic of
yeast and mammalian cells strongly suggest that the in
tracellular, physiological conditions of yeast and mammalian
cells are quite similar.

One of the main advantages of this

system is the extensive repertoire of genetic techniques
applicable to studies in yeast (Struhl, 1983) which allow
for a combination of molecular biology and genetic ap
proaches for studying cellular functions. The other ad
vantage is that the time-frame required to carry out experi
ments is shorter in a yeast system than in a mammalian cell
culture system, since yeast*s average doubling time is 90
minutes. The parameters that can be addressed in yeast are
1) determination of the effects of levels of expression of
ribozyme versus target sequences on catalytic efficiency, 2)
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the influence of extra nucleotides on ribozyme stability and
activity, 3) chromosomal versus episomal expression, 4)
nuclear versus cytoplasmic localization, 5) enhancement of
the catalytic center formation by increasing the stability
of the center itself, and 6) the effect of simultaneous
targeting of multiple ribozymes to the same substrate. Two
synthetic anti-lacZ ribozymes have been expressed intracellularly in yeast. The intracellularly expressed anti-lacZ
ribozymes were demonstrated to be biologically active by an
in vitro cleavage reaction. Using a S. cerevisiae actin-E.
coli lacZ construct as a reporter gene, the stage is set for
the utilization of this yeast system for the rapid and
quantitative evaluation of a wide variety of ribozyme
parameters.

MATERIALS AND METHODS
Reagents. T7 RNA polymerase and human placental RNase
inhibitor were obtained from BioRad. T3 RNA polymerase was
obtained from Stratagene. T4 polynucleotide kinase was
obtained from New England Bio-Labs. AMV reverse transcrip
tase was obtained from Life Sciences.
lipofectin

T4 DNA ligase,

reagent and restriction enzymes were obtained

from Bethesda Research Lab. Tag DNA polymerase was obtained
from Perkin-Elmer-Cetus.

[a-^PJUTP, [r-^PJATP, [a-^PJdCTP

and 3H-cholesteryl hexadecyl ether were obtained from New
England Nuclear. Phospholipids were obtained from Avanti
Polar Lipids, Birmingham, Ala. Cholesterol was obtained from
CalBiochem, San Diego, Cal.

Dulbecco modified Eagle medium,

fetal calf serum and Opti-MEM 1 reduced serum medium were
obtained from GIBCO, Grand Island, N.Y.

Synthetic oligo-

deoxyribonucleotides were either prepared on an Applied
Biosystems Model 38OB DNA synthesizer by the DNA synthesis
core facility (Beckman Research Institute of City of Hope)
or by Genetic Designs Inc, Houston, Tex.
Plasmid constructions for in vitro cleavage reactions.
Plasmid pBH10-R3 containing a 8.9 kb SstI DNA insert of
HIVHXB2 provirus (Ratner et al., 1987) was obtained from
Biotech Research Laboratories, Rockville, MD. This 8.9 kb
SstI insert represented the complete sequences of the
HIVHXB2 provirus except the 5'LTR and 3

LTR, which rendered

it non-infectious. The coordinates of the insert are 675-
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9602. All of the coordinates presented in this dissertation
are based on the HIVHXB2 sequence with the first base in the
5' LTR as base 1. The entire DNA insert was subcloned into
the pBLUESCRIPT-KS(+) vector (Stratagene) resulting in
plasmid pBKBHIO-S (Fig. 4). The orientation of the 8.9
kilobase DNA insert was such that an in vitro transcription
from the T7 promoter would produce a sense RNA.

A further

subcloning of a 383 basepair Hindlll-Bglll fragment (coo
rdinates: 1710 to 2093) from pBKBHIO-S into the Hindlll and
BamHI sites of the pBLUESCRIPT-KS(+) vector resulted in
plasmid pBKHAM-4 (Fig. 4). The orientation of these inserts
was such that an in vitro transcription from the T3 promoter
would produce sense RNA.

Both pBKBHIO-S and pBKHAM-4 plas-

mids, after being linearized by an appropriate restriction
endonuclease, were used as templates for the in vitro
transcription reactions to generate the target RNAs as
substrates for the in vitro cleavage reactions (described
below).
pBKGAG-HAM and pBKGAL-HAM were derived from
pBLUESCRIPT-KS(+) by cloning the appropriate synthetic
ribozyme genes (Fig. 4). These synthetic ribozyme genes
ranged from 58-75 basepairs and contain flanking
endonuclease restriction sites (Fig. 4). They were each
prepared by filling the corresponding sets of two singlestranded oligodeoxyribonucleotides, approximately
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Figure 4. Plasmid maps for templates used in synthesizing A)
substrates and B) ribozymes for in vitro cleavage reactions.
Both the substrates and ribozymes are produced by in
vitro run-off transcription reactions.
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Figure 5. Schematic of A) an in vitro polymerization reac
tion for synthesizing ribozyme gene and B) an in vitro
transcription of ribozyme from synthetic DNA templates.
A) Two single stranded oligo-deoxyribonucleotides with
endo-ribonuclease recognition sequences on their 5' ends and
10 bases of complementary sequence to each other at their 31
ends are used to synthesized the double stranded ribozyme
gene by using an in vitro polymerization reaction mediated
by Tag polymerase.
B) Ribozymes are synthesized from a hemi-double
stranded synthetic oligo-deoxyribonucleotide template con
taining a single stranded ribozyme coding region and a
double stranded T7 RNA promoter region. The promotor is 18
basepairs long and is made functional by the annealing of a
promoter sequence specific oligo-deoxyribonucleotide to the
single stranded template.
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bases long each, containing 10 bases of complementarity to
each other at their 3' termini (Fig. 5a).

The double

stranded DNAs were synthesized by a modified in vitro poly
merization reaction adapted from Rossi et al.

(1983). The

modified in vitro polymerization reactions utilized the
polymerase chain reaction (PCR) buffer (described below) in
a final volume of 50 /il. The two single-stranded oligodeoxyribonucleotides were at 1 /iM each with 200 /iM of each dNTP,
and 2 units of Tag DNA polymerase were added to initiate the
synthesis. The polymerization was done for ten cycles in a
Perkin Elmer Cetus DNA Thermal Cycler using conditions
similar to that described for the PCR procedure,

The fidel-

ity of the DNA synthesis, polymerization and orientation of
the inserts were checked by dideoxy sequencing of cloned
products.
pBKGAL-HAM contained a one base pair mismatch in the
stem II region of the ribozyme. To correct the mismatch,
pBKBHAM-aF (Fig. 4) was constructed by site directed PCR
mutagenesis. A oligodeoxynucleotide containing the correct
sequence was used as one of the two primers for PCR while
the other primer was a T3 primer (reverse primer).

The

template used for the PCR mutagenesis was plasmid pBKGALHAMaF, derived from pBKGAL-HAM by adding a-factor transcription
terminator region into the Sail site. The amplified products
were cloned into the BamHI and Xhol sites of the
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pBLUESCRIPT-KS (+) vector. The orientation and the
mutagenesis were checked by dideoxy sequencing.
Plasmid construction for the mammalian expression
system. pPC-RAG12 (Fig. 18) was derived from pHBAPr-l-gpt
(Gunning et al., 1987) by cloning the synthetic GAG-HAM
ribozyme insert into the vector's BamHI site. This vector
contains the human B-actin promoter and SV-40 late
transcriptional termination and poly adenylation signals
(Fig. 18). The synthesis of the insert and the cloning
procedures were similar to that described for pBKGAG-HAM.
Plasmid constructions for the yeast system. Plasmid
pYGH2PC was derived from pYEP24 (Botstein et al., 1979) by
cloning an insert containing GAL1-10 promoter, GAL-HAM
ribozyme and a-factor transcription terminator region iso
lated from pSPGH-PROaF (Fig. 6). This insert was constructed
by first cloning the GAL1-10 promotor taken from pBM150
(Johnston and Davis, 1984), a 1.2 kb DNA with BamHI and
EcoRI ends, into pSP72 (Promega), resulting in pSPGALPRO
(Fig. 6) . The GAL-HAM ribozyme gene from pBKGALHAM was
ligated to pSPGALPRO at the Xbal and Xhol sites resulting in
pSPGAL-HAMPRO (Fig. 6). The ribozyme was inserted such that
it would be under transcriptional control of a GAL1
promotor. An a-factor terminator region, previously cloned
into pSP72 plasmid, was isolated following Sail digestion
and ligated to pSPGAL-HAMPRO at the Sail site to produce

O

Figure 6. Plasmid maps for the constructions of anti-lacZ ribozyme cloned into two
types of yeast expression vectors.
Plasmid pYGR2PC is a 2-micron circle based vector capable of maintaining high copy
number in a host cell. Plasmid pYGRCPC is a single copy number plasmid containing a
copy of a centromere (CEN3) and an origin of replication (ARS1). Cloned anti-lacZ
ribozyme genes in both plasmids, are under the controls of an inducible promotor (GAL1)
and contain a copy of a-factor transcription termination sequences. The same biosyn
thetic selection markers (URA3) is used for both plasmids.
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pSPGH-PROaF. The orientation of the terminator was checked
by a series of restriction digests. The final cloning step
was to transfer the ribozyme genes with the promoter and
terminator to the yeast shuttle vector pYEP24 by ligating
the ribozyme gene with BollI and Xhol ends to the vector's
BamHI and Sail sites.
Plasmid pYGHCPC (Fig. 6) was cloned by ligating a BamHI
insert isolated from pSPGH-PROaF containing the GAL-HAM
ribozyme gene and the a-factor terminator region into the
pBM150 BamHI site. The orientation of the insert was checked
by a series of restriction digests.
In vitro transcription of RNA from synthetic DNA
templates. The transcription reactions were adapted from
Lowary et al.

(1986) and Zaug et al. (1986). An oligodeoxy-

ribonucleotide containing the sequence of the bacteriophage
T7 RNA polymerase promoter and a sequence complementary to
the desired RNA product, was mixed with an 18 base oligodeoxyribonucleotide complementary to the bacteriophage T7
promoter segment, forming a hemi-duplex (Fig. 5B).

The

transcription reactions contained 2/xM of each oligodeoxyribonucleotide, 0.5 unit/^l T7 RNA polymerase, 40 mM Tris-HCl
pH 7.9, 20 mM MgCl2, 10 mM NaCl, 10 mM DTT, 1.0 mM ATP, CTP
and GTP , 0.1 mM UTP, 10 iiCi of [a-^PjUTP and 1 unit/^l
human placental RNase inhibitor in a 50 /il volume. The
reactions were carried out at 40°C

for 1 hour and the

43
products purified by gel electrophoresis (described below).
When RNA with a 5' GpppG cap was transcribed, all the condi
tions were similar to that for the uncapped reaction except
that GTP concentration was reduced to 0.2 mM and 1.0 mM of
GpppG cap analog was added to the reaction mixture.
In vitro transcription of RNA from plasmid templates.
Transcriptions of RNAs from plasmid templates, utilizing
either the T7 promoter or T3 promoter and the corresponding
polymerase, were carried out under conditions similar to
those described above for in vitro transcription of RNA from
synthetic DNA templates. The plasmid templates were linearlized with an appropriate restriction endonuclease for run
off transcription.

The plasmid template concentrations in

the reaction mixtures were 0.05 /xg//il. The product RNAs were
gel purified as described below.
Gel electrophoresis and purification of RNAs. Cleavage
reactions, transcription mixtures or dideoxy sequencing
reactions were added to an equal volume of loading solution
( 95% formamide, 1 mM EDTA, 0.1% (w/v) Xylene cyanol and
0.1% (w/v) bromophenol blue), heated at 65°C for 5 minutes
and loaded onto 40 cm x 0.5mm x 20 cm, 7M ureapolyacrylamide gels of an appropriate percentage,

The

running buffer was IX TBE (45mM Tris-borate pH 8.4 and 1.25
mM EDTA). Autoradiography was carried out at -70°C with an
intensifying screen for the detection of labelled RNA.

For
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RNA purification, a brief exposure of the gel at room tempe
rature was sufficient to detect the labelled RNA.

Gel

slices containing the RNA were eluted for several hours at
room temperature by vortexing in 0.1% SDS, 0.5 M ammonium
acetate pH 6.9, 1 mM EDTA. The eluates were filtered through
Costar Spin-X filters, precipitated by the addition of 0.1
volume of 3 M sodium acetate pH 5.2, and 2 volumes of 95%
Ethanol.

The RNAs were allowed to precipitate at -20°C for

one to several hours before centrifugation.
In vitro cleavage reactions. The reactions were carried
out in a 10/il or 20/li1 volume.

Ribozyme and target RNAs

(usually 1 pmol of each), both in 75 mM Tris-HCl pH 7.5 and
1.5 mM Na-EDTA (Buffer A), were mixed together at the
desired molar ratios and heated to 95°C for 2 minutes fol
lowed by fast cooling on ice.

The reactions were initiated

by adding MgCl2 and either buffer A or dH20 to the mixtures
to make a final concentration of 50 mM Tris-HCl pH 7.5,
either lOmM or 20 mM MgCl2 and 1 mM Na-EDTA.

The reactions

were then overlain with 1.5 volumes of mineral oil to
prevent condensation, and incubated at 37°C unless specified
otherwise. The reactions were stopped by the addition of 0.2
volumes of 200 mM Na-EDTA pH 7.9.

The standard incubation

times were 14 hours unless specified differently in the
figure legends. The cleavage products were analyzed by
polyacrylamide/urea slab gel electrophoresis.
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DNA sequencing. The plasmids containing the insert to
be sequenced were prepared by conventional plasmid prepara
tion (either mini-preparation or large scale preparation)
which included the removal of digested RNAs. To remove any
small contaminating RNAs remaining with the plasmids, 0.6
volume of 20% PEGsooo”2.5 M NaCl was added to the plasmids.
the mixture stored on ice for 1 hour, centrifuged at 10,000x
g for 5 minutes, and the pellet rinsed with 70% ethanol and
dried.

The pellet (containing 3-5 nq of DNA) was resuspend

ed in 18 fil of TE buffer ( lOmM Tris-HCl pH 8.0, 1 mM NaEDTA) and 2 fil of 2N NaOH were added to denature the plas
mids. The mixture was incubated at room temperature for 5
minutes followed by the addition of 8 ^1 of 5M NH4-acetate
pH 7.4 and 100 ill of 95% ethanol. The denatured plasmids in
ethanol were stored at -70°C for 5 minutes, centrifuged at
10,000x g for 5 minutes, the pellet rinsed with 70% ethanol
and dried.

The denatured plasmids were resuspended in 10 /xl

of TE buffer and ready for use in the dideoxy sequencing
technique as recommended by the manufacturer (Sequenase,
United States Biochem. Corp.).
RNA sequencing. The dideoxy sequencing of RNA was
adapted from Inoue and Cech (1985) using a 17 base long
oligodeoxyribonucleotide complementary to a region that is
14 to 28 bases downstream (to the 3' side) of the cleavage
site. The primer was 5* end labeled with r-32? ATP using T4
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polynucleotide kinase followed by ethanol precipitation. The
RNA and the primer were mixed at 1:10 molar ratio in 10/xl of
the hybridization buffer (60 mM NaCl, 10 mM DTT, 50 mM TrisHC1, pH 8.3) and heated to 60°C for 3 minutes,

The mixture

was allowed to gradually cool to 30°C over 60 minutes. Next,
2jLtl of 36 mM MgCl2 in hybridization buffer were added.
Sequencing reactions, one for each ddNTP and one without
ddNTP, were allowed to proceed at 37°C for 30 minutes in a
5jul final volume ( 2/xl of the RNA/primer solution and 3/xl of
the hybridization buffer containing 625 /xM of each dNTP, 6
mM MgCl2, 3 33 /iM of one of the ddNTP and 1 unit of reverse
transcriptase).

Electrophoresis was in a 15% polyacryl-

amide/7M urea slab gel.
Microinjection of RNA into Xenopus oocytes and total
RNA extraction. The procedure was that of Gurdon and Wake
field (1986).
Cell culture, lipofection and selection for ribozyme
clones. HeLa CD4+ cells (Maddon et al., 1986) were obtained
from the NIAID Research and Reference Reagent Program and
grown in Dulbecco's Modified Eagle Medium(DMEM) supplemented
with 10% fetal calf serum(ECS). Fifty percent confluent
cells were washed with serum free media three times, to
remove any ECS, and transfected with lipid-DNA complexes of
lipofectin reagent-plasmid (pPC-RAG12) at a 10 ng:l fig ratio
in a Opti-MEM 1 reduced serum medium(RSM)

(Feigner et al..
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1987). The lipid-DNA complexes were prepared by mixing the
lipofectin reagent, diluted in 1.5 ml Opti-MEM 1 RSM, with
the plasmid pPC-RAG12 diluted in 1.5 ml Opti-MEM 1 RSM. Upon
mixing, the complexes were then added directly to the washed
cells.

The mixtures were incubated at 37°C for 5 hours

followed by addition of 10% FCS DMEM to inactivate the
lipofectin reagent. The cells were incubated under growth
conditions for three days.

They were then treated with

trypsin-EDTA, and 5 x 104, 1 x 105 and 5 x 105 cells were
dispersed in duplicate into 60 mm tissue culture plates in
DMEM containing 10 % FCS, 250 /xg/ml xanthine, 15 nq/ml
hypoxanthine, 25 /xg/ml adenine sulfate, 10 ng/ml thymidine,
2 /xg/ml aminopterin and 5 fiq/ml mycophenolic acid to select
for the

expression of the E. coli xanthine-guanine phospho-

riboxyltransferase (gpt) gene (Mulligan and Berg, 1981) .
After 10-14 days of selection, individual colonies were
picked. Sterile cotton swaps pre-soaked in DMEM were used to
lightly scrape off the cells from the colonies. Each cotton
swap was then rinsed with DMEM to recover the transformed
cells. The recovered cells were dispersed into 60 mm tissue
culture plates and grown in DMEM containing the above selec
tive agents.

The transformants expressing GAG-HAM ribozyme

were screened using the polymerase chain reaction assay
described below.
After six months of growth in selective media, the
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transformants were slowly weaned off the selective agents
over the period of four weeks, with a 25% reduction in the
selective agents per week. Cell viability was tested by the
addition of 0.1 % trypan blue solution to check for dye
uptake into non-viable cells.
HeLa CD4+ and H9 lymphocytes total RNA preparation. The
isolations of total RNA

were carried out using RNAzol

(Cinna/Biotecx Lab.). HeLa CD4 cells were trypsinized,
washed and pelleted whereas the H9 cells were directly
washed and pelleted. RNAzol reagents (0.2 ml of RNAzol per
106 cells) were added to lyse the cells by passing the
lysate a few times through the pipette. After all the cells
were lysed, 0.1 volume of chloroform was added to the
lysate, vortexed for 15 seconds, stored on ice for 15
minutes and centrifuged at 10,000x g for 15 minutes at 4°C.
The top aqueous layer containing the RNA was extracted and
the RNA was precipitated using an equal volume of isopropanel.

The RNA pellet was washed twice with 0.8 ml of 75%

ethanol and dried.
The selections of poly (A)+ RNA from the total RNA were
as described by Maniatis et al.

(1982).

Polymerase chain reactions (PCR). The procedure follows
that of Saiki et al.

(1985) as modified by Murakawa et al.

(1988) . The amount of total RNA used was 200ng per 50 /il
final volume of PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM
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KC1, 15 mM MgCl2, 0.1% (w/v) gelatin, 200 /iM of each dNTP) .
The reverse transcription step was performed at 40°C for 3
minutes with only the first strand primer (0.4 /xM) in the
reaction mixtures with 2.5 units of AMV reverse transcrip
tase, followed by the addition of the other primer (0.4 /xM)
and amplification of the reverse transcribed DNA by the
addition of 2.5 units of Tag DNA polymerase. The PCR assay
was performed for 30 cycles in a Perkin Elmer Cetus DNA
Thermal Cycler. Each cycle was comprised of a denaturation
step at 94°C for 1 minute, a annealing step at 45°C for 1.5
minutes and a polymerization step at 72°C for 2 minutes. To
minimize condensation, 50 /xl of mineral oil was added to the
reaction mixtures. The amplification products were analyzed
by 1.5% agarose gel electrophoresis in 0.5X TBE buffer.
After staining the gel with ethidium bromide, the amplified
products were transferred onto a nylon membrane (Zeta Probe,
BioRad) by alkaline vacuum blotting using a home-made blott
ing apparatus and 0.5 M NaOH (Reed and Mann, 1985). The
membranes were then neutralized in 6X SSC (0.9 M NaCl, 90 mM
sodium citrate pH 7.0)

probed with a 32P-labelled, sequence

specific oligodeoxyribonucleotide in 6% SSPE (0.9 M NaCl, 6
mM NaH2P04, 6 mM sodium-EDTA pH 7.4), 7% SDS and 0.5% "Blo
tto" powdered milk at 55°C overnight.

The filter was washed

3 times with 6X SSC at 60°C for 5 minutes each and autoradiographed.
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Northern gel analysis for the detection of intracel
lular expressed ribozyme and the uptake of free ribozyme.
Electrophoresis were performed as described above in a 6%
polyacrylamide-7 M urea slab gel with 7.5-10 jug total RNA or
poly(A)+ RNA loaded per lane. The RNAs were electroblotted
onto a nylon membrane in IX TAE (40 mM Tris-acetate pH 7.2,
20mM sodium acetate 1 mM sodium EDTA) at 0.8 Amp for 14
hour. The membrane was then fixed by UV, and probed using a
32P-labelled ribozyme specific, 36 base long oligodeoxyribonucleotide.

The hybridization was in 6X SSPE, 7% SDS, 10X

Denhardts medium (0.2% BSA, 0.2% Polyvinylpyrrolidone, 0.2%
Ficoll) at 70°C overnight,

The filter was washed 3 times

with 6X SSC at 65°C for 5 minutes each and autoradiographed.
Free ribozyme uptake experiment. The H9 cells targeted
for uptake were treated with 10 /xg of Polybrene per ml of
cell suspension for 30 minutes and washed with serum free
media. The cells were pelleted at lOOOx g for 5 minutes and
resuspended in serum free media containing free ribozymes.
The cells plus ribozyme were incubated at 37°C for one hour
and washed again with serum free media.
HIV-1 infection and viral antigen assay. The HIV-1
infection of the H9 lymphocytes in the transient ribozyme
protection experiment and the HeLa CD4 cells expressing GAGHAM ribozyme were described by Zaia et al.

(1988). The

antigen quantitations were that of HIV p24 Core Profile
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ELISA Kit as recommended by the manufacturer (Dupont).
Liposome encapsulation of ribozyme.

The liposome and

the encapsulation of ribozyme were performed by Vestar
Company, San Dimas, Cal. Lipid films were prepared by first
dissolving the phospholipids and cholesterol in chloroform.
3H-cholesteryl hexadecyl ether was added to the chloroform
lipid solution as a non-transferable, non-degradable lipid
marker.

The solvent was evaporated under nitrogen, yielding

a dry lipid film.

Residual chloroform was removed by vacuum

desiccation overnight.

The films were then hydrated with

either phosphate buffered saline (137mM NaCl, 2.7 mM KC1 and
10 mM phosphate, pH 7.4- PBS) or PBS containing 100 fig to
300 /ig of ribozyme.

Suspensions were heated to 65°C and the

lipid was vortexed into suspension. An aliquot was removed
to determine the specific activity of the lipid. The suspen
sions were frozen in liquid nitrogen and thawed at 65°C and
the freeze and thaw cycle was repeated two more times,

The

lipid suspensions were then formed into unilamellar lipo
somes by extruding each suspension through a 0.4 /m and 0.2
polycarbonate filters (Nucleopore) at 800 psi using an
extruder (lipex Biomembranes, Vancouver, B.C.).

Each sus

pension was brought through each filter three times,

The

unencapsulated ribozyme was removed by a Biogel ASM gel
filtration column (Bio-Rad). The liposomes eluted in the
void peak. The lipid fractions were collected and sterile
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filtered through a 0.2 /Ltm polycarbonate filter. Liposome
size was determined by quasi-elastic light scattering using
a Nicomp Model 370 submicron laser particle sizer,

The

liposomes were on the average of 150nm in diameter. Encapsu
lated ribozyme concentrations were determined by using
labeled ribozyme or extracting the lipid with chloroform/methanol (1:1) and measuring the absorbance at 260 nm.
Preparations yielded approximately 10 to 14 ribozyme mole
cules per liposome.
Northern blot analysis for the detection of the lipo
some delivered ribozyme. The procedure used was the modified
formaldehyde-agarose gel electrophoresis (Davis et al.,
1986) employing a 2.0 percent agarose gel. A standard capil
lary transfer procedure was used to transfer RNA onto a
nylon membrane (Zeta probe, BioRad). The hybridization was
that described for northern analysis above.
Yeast growth media. Yeast Saccharomvces cerevisiae
strain JM43 (a, trpl, ura3-52, his3A-l, gal2, gallO) was
grown in YPD media ( 1% yeast extract, 2% Bacto peptone, 2%
glucose) before transformation. All other subsequent trans
formants were grown in the appropriate synthetic minimal
media (0.67% yeast nitrogen base without amino acids, 2%
glucose or galactose, 20mg/l of histidine omitting either
20mg/l of uracil or 20 mg/1 tryptophan or both, depending on
the complementation of the plasmid biosynthetic genes). All
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growth was performed at 30°C with good aeration.
Yeast transformation. Yeast cells were transformed
using the lithium acetate procedure previously described by
Ito et al.

(1983). Yeast strain JM43 was grown in 50 ml of

YPD to a density of 1-2 x 107 cells/ml ( 00600=0.5-1.0) and
harvested

by centrifugation at 4000x g for 10 minutes. The

pellet was washed with 10 ml of TE buffer followed by a
second wash using 10 ml lithium acetate solution ( 0.1 M Liacetate, 10 mM Tris-HCl pH 8.0, 1 mM Na-EDTA). Both washes
were done by resuspending the cells and repelleting them.
The washed pellet was resuspended in 500 /xl of lithium
acetate solution and incubated at 30°C for 1 hour with
gentle shaking ( 50 rpm). To each 100 nl of competent cells,
1 to 10 /ng donor DNA plus 20 /zg carrier DNA (herring sperm
DNA)

were added by gently pipetting up and down. The mix

ture was incubated at 30°C for 30 minutes without shaking.
After this, 0.7 ml PEG solution (40% PEG4ooo in lithium
acetate solution) was mixed by pipetting gently with the
mixture and incubating at 30°C for 60 minutes. The yeast-DNA
mixture was subjected to 42°C heat shock for 5 minutes.
harvested by centrifugation at 10,000x g for 5 seconds and
washed with 0.5 ml of TE buffer.

The cells were resuspended

in 100 /zl of TE buffer and plated on the appropriate syn
thetic minimal media.
Yeast total RNA preparation.

The preparation of total
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yeast RNA was adapted from Domdey et al.

(1984). Yeast cells

were grown in 10 ml of the appropriate synthetic minimal
media until AeocpO.8-1.5 and harvested by centrifugation at
4000x g for 10 minutes. The cell pellet was resuspended in
400 jxl of ice cold 50mM Na acetate, pH 5.3, 10 mM Na-EDTA
(buffer D). Forty microliters of 10% SDS were added to the
suspension and vortexed for 2 minutes to completely lyse the
cells.

The cell lysate was extracted with an equal volume

of phenol, pre-equilibrated with buffer D, at 65°C for 4
minutes. The mixture was rapidly cooled in a dry-ice/acetone
bath until phenol crystals appeared. After centrifugation
for 5 minutes at 10,000x g,

the upper aqueous layer con

taining the RNA was transferred to a fresh tube and a second
extraction was preformed. In all the extractions, the thick
interface was left behind. After the second phenol extrac
tion, an equal volume of 1:1 v/v phenol/chloroform was used
for the last extraction.

The aqueous phase was brought to

0.3 M Na-acetate (final concentration) and 2.5 volumes of
95% ethanol were added to precipitate the RNA.

Approximate

ly 0.5 mg of total RNA was recovered from this procedure.

RESULTS
Autocleavage of HIV-1 RNA.
We reasoned that a "hammerhead" model I ribozyme (Fig.
2) could be generated with HIV-1 RNA by identifying two of
the required nucleotide sequences in HIV-1 (GAAAC and GUN
where N is any nucleotide except for guanosine) with the
third required sequences (CUGANGA) being supplied in trans
by an in vitro transcribed ribozyme.

Using this approach,

11 possible targets were identified in HIVHXB2 proviral DNA
(Ratner et al., 1987)

(Figure 7).

We choose the first GAAAC

closest to the 5'end of our proviral clone pBKBHIOS as our
initial target site. This site corresponds to the second
GAAAC sequence with GUN cleavage domian 11 nucleotides 3' of
the GAAAC domain as shown on figure 7.

We synthesized a 43

base long catalytic strand (Fig. 8, ribozyme A) by in vitro
transcription using a synthetic oligo-deoxyribonucleotide
template.

This synthetic RNA supplied the third block of

required nucleotides for the formation of the catalytic core
of the hammerhead model when the complementary sequences
base paired correctly with the targeted sequences centered
around the GAAAC-----GUA block in the HIV-1 gag gene. When
this ribozyme was incubated in a 2:1 molar ratio of ribozyme
to substrate ( a 403 nucleotide long HIV-1 gag RNA trans
cribed in vitro) for 1 hour at 45°C with increasing amounts
of MgCl2, cleavage of the substrate, as monitored by the 5
cleavage product, was observed at a very low efficiency as a
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Figure 7. Locations of possible cleavage sites for model I
ribozymes in the HIV-1 genome.
To identify the possible cleavage sites for the model I
ribozyme, the occurrences of GAAAC were searched for in
HIV-1 sequences using HIVHXB2 as our model sequence (GenBank
and EMBL accession number K03455). All of the coordinates
presented in this dissertation are based upon the HIVHXB2
sequence with the first base in the 5'LTR as base no. 1.
The eleven identified sites are indicated by the ar
rows. The sites targeted for ribozyme A (Fig. 8) and ribozyme B (Fig. 9) are the first and the second GAAAC in the
gag gene and include the GUA and GUC cleavage sites, respec
tively. The coordinates for each target site are 941 to 960
(GAAAC through GUA) for ribozyme A and 1743 to 1757 (GAAAC
through GUC) for ribozyme B. For ribozyme B, the GUU which
immediately follows the GAAAC was not used since most of
the natural occurring "hammerhead" ribozymes involve clea
vage after a GUC.
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Figure 8. The in vitro cleavage activity of ribozyme A.
The starred nucleotides(nts) indicate the essential
bases for formation of the catalytic center of the "hammer
head" ribozyme. Half of the catalytic center including the
cleavage site is composed of viral sequences as well as the
depicted stem III. The stem III is a 5 basepair region with
one mismatch to destabilize it.
Ribozyme A was assayed for its cleavage activity of an
in vitro transcribed, 419 nts long gag substrate (nucleo
tides 675-1084 plus 10 nts of polylinker at the 5* end of
the transcript derived from the transcription vector). The
reaction was carried out at a 2:1 molar ratio (2 pmol:l
pmol) of ribozyme to substrate and incubated at 45oC for 1
hour in the presence of increasing concentration of MgC12.
Lane: M, Hoa II-digested pTZ18U molecular weight markers; A,
substrate without added ribozyme, lOmM MgCl2; B, ribozyme A
plus substrate, 20mM MgCl2; C, ribozyme A plus substrate,
0.5mM MgCl2? D, ribozyme A plus, ImM MgCl2; E, ribozyme A
plus substrate, 5mM MgCl2. The position of the 5' cleavage
products are indicated.
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function of the MgCl2 concentration (Fig. 8). The 5' cleav
age products were most prominent in the reaction containing
20 mM MgCl2 (lane B) and decreased in intensity until none
were detected in reactions containing less than 5 mM MgCl2
(lanes C,D and E).

We decided that the low cleavage ac-

tivity was due to the inability of this trans-acting ribozyme to form a stable stem III, which has been proposed to
be crucial for the efficient ribozyme-mediated cleavage
reaction (Forster et al. 1988). The stem III of ribozyme A
was being stabilized by a four base pairs stem interrupted
by one mismatch and flanked by a relatively large loop (Fig.
8) .
Subsequently, sequences adjoining each of the 10 GAAAC
elements were then screened for a GUN downstream of the
GAAAC.

Those regions in which a GUN was within close proxi

mity, and could possibly form a stable hammerhead structure
when base-paired with the trans-supplied sequence, were
scrutinized further.

The next target we utilized was the

second GAAAC in the gag gene (Figure 7), and here two of the
elements (GAAAC and GUC) which must be brought into close
proximity were only seven nucleotides apart. Thus, the
targeted sequences in the HIV-1 gag gene could be paired
with an exogenously supplied strand containing the required
CUGANGA and flanking sequence complementary to the target
site (see Figure 9, ribozyme B).

It was important for the
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Figure 9. Comparison of the catalytic efficiencies of ribozyme B (model I) and ribozyme c (model IV)•
The starred nucleotides(nts) indicate the essential
bases for formation of the catalytic center. Two different
classes of ribozymes targeted to the same gag cleavage site
(between nts. 1757 and 1758) are depicted. Ribozyme B re
quires viral sequences to provide half of the catalytic
center including the stem III. In contrast to ribozyme B,
ribozyme C contains all of the required nucleotides in the
catalytic strand except for the cleavage site.
Ribozymes B and C were assayed for their relative
catalytic efficiencies in cleaving an in vitro transcribed,
138 nts long gag substrate (nucleotides 1711-1789 plus 60
nts of polylinker at the 5' end of the transcript derived
from the transcription vector). Two different forms, ribo
zymes containing a cap analog (GpppG) at their 5' end (lane
1) and ribozymes without any modification (lane 2), of each
ribozyme were tested. The reactions were carried out at a
1:1 molar ratio of substrate to ribozyme under standard in
vitro cleavage reaction conditions containing lOmM MgCl2.
Lane: m, HpalI-digested pBR322 MW markers; B, ribozyme B
plus substrate; C, ribozyme C plus substrate; S, substrate
without added ribozyme. Ribozymes positions are indicated by
the open arrows and the 5' (103 nts) and 3' (heterogenous
bands around 35 nts) cleavage products by the solid arrows.
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sequence chosen to have the capability of forming a rela
tively stable stem III. In this region,a three base pair
stem with a five nucleotide loop could be formed,

bringing

the required, targeted nucleotides of HIV-1 into the proper
juxtaposition. When this second ribozyme, a 23 base-long
catalytic strand, was incubated in equimolar amounts with
the 138 nucleotide long in vitro transcribed gag substrate,
cleavage of the substrate into two fragments of the expected
size (Fig. 9, lane Bl) was observed at a much higher ef
ficiency as compared to ribozyme A (Fig. 8). The smaller
cleavage product was actually composed of several fragments
of heterogenous lengths.

This heterogeneity was shown by

direct sequencing to be at the 3' end of the gag transcript,
a product of erratic stopping of the in vitro transcription
reaction, and not a variation in the cleavage reaction (see
below).
The catalytic efficiency of ribozyme B was examined
under several different temperatures (Figure 10, panel B) .
Surprisingly, the cleavage efficiency was uniform over a
rather broad range of temperatures, decreasing somewhat at
55°C.

It should be noted that in contrast to the results

described below, complete cleavage of the substrate using
ribozyme B was never observed under our cleavage conditions.
Subsequent to our studies with this ribozyme, Haseloff
and Gerlach (1988) published studies of model IV

o\
•t*

Figure 10. Comparison of temperature versus activity profiles of ribozymes B and C
targeted to the same gag substrate.
Ribozyme B (panel B) or C (panel C) was mixed at a 1:1 molar ratio ( 0.1/iM of each)
with the gag substrate described in the figure 9 legend. The reactions were carried out
under standard in vitro cleavage reaction conditions at the indicated temperature in
presence of 20 mM MgCl2. The exception was the lane marked 55 with the overlying bar,
which had no MgCl2 in the incubation mixture but did include substrate and ribozyme
and was incubated at 55°C. In these experiments, the ribozymes themselves are at the
very bottom of the gel. The substrates (S), 5' and 3' cleavage products (P) are the
same as described for Figure 9.
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trans-acting ribozymes targeted to the bacterial CAT gene.
Their ribozyme design was based upon the structure of the
catalytic center of the satellite RNA of Tobacco Ringspot
Virus, and harbored two of the three required ribozyme
elements (Figure 9, ribozyme C).

This ribozyme design

allows much greater flexibility in the choice of target
sites and greater stability of the stem III.

Utilizing the

same gag RNA substrate, we designed a catalytic RNA (ribo
zyme C) modeled from the method of Haseloff and Gerlach.

A

direct comparison between the two catalytic RNAs, ribozyme B
and C, was carried out on the 138 nucleotide gag template
(Fig. 9).

At a 1:1 ribozyme to substrate ratio, the ribo

zyme C effected complete cleavage of the substrate at 37°C
following a 14 hour incubation (lane Cl), whereas ribozyme B
did not completely cleave the target under these same condi
tions (lane Bl). In this study, the two catalytic RNAs were
also transcribed in the presence of the cap analog, GpppG,
to determine whether addition of a 5' cap structure affected
the ribozyme function and efficiency.

The capped ribozyme

produced in these transcription reactions functioned at the
same efficiency as the uncapped counterpart (compare lanes
Bl to B2 for ribozyme B and lanes Cl to C2 for ribozyme C).
When temperature profiles for these uncapped ribozymes were
carried out (Figure

10), relatively uniform cleavage activ

ity was also observed over a broad range of temperatures,
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with substantial activity at 37°C.
The heterogeneity of the shorter 3' cleavage product
with both ribozymes B and C prompted further investigation
of the specificity of the cleavage site.

To do this, a

5' end labelled synthetic oligodeoxyribonucleotide, com
plementary to HIV-1 gag RNA sequences downstream of the site
of cleavage was utilized as a primer for reverse transcrip
tase-mediated dideoxy sequence analysis of the reaction
products depicted in Figure 11A.

The sequence obtained

demonstrates that the cleavage site is between the nucleo
tides predicted from our model (Figure 9). Interestingly,
but unexpectedly, a small amount of cleavage occurred bet
ween the U and C nucleotides immediately upstream of the
targeted C nucleotide (see Figure 9, ribozyme C).

Most

importantly, we concluded that the observed heterogeneity of
the smaller cleavage product in Figure 9 lanes Cl and C2,
was due to multiple, in vitro transcriptional termination
sites and/or addition of a non-template encoded nucleotide
at the 3

end of the transcripts. These phenomena has also

been reported by others (Milligan et al., 1987; Krieg and
Melton, 1987).
Time course of the cleavage event
Ribozyme C was incubated with an equimolar amount of
the 138 nucleotide long gag target transcript for varying
amounts of time at 37°C (Figure 11B).

Under these

<J\
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Figure 11. A) Verification of the cleavage site by dideoxy sequencing using reverse
transcriptase and B) time versus activity profiles of ribozyme C.
A) The cleavage products from ribozyme C and the 138 nts gag substrate incubated
under conditions identical to that described in the Figure 9 legend were subjected to
dideoxy sequence analysis. Both primer extension (lane o) and dideoxy sequencing were
utilized to verify the cleavage sites. The sequencing primer was complementary to
sequences downstream of the cleavage site. The actual sequence obtained is complemen
tary to the gag RNA, but for convenience, the RNA sequence is presented and can be
matched with the gag sequence presented in Figure 9.
B) Ribozyme C activities were assayed under standard cleavage reaction conditions in
the presence of 10 mM MgCl2 and at a 1:1 substrate (138 nts gag transcript) to ribozyme
molar ratio (0.1 /xM of each). The reactions were stopped after the times indicated
below. Lanes: M, Hpa II-digested molecular weight markers; A, 4 hours incubation
without MgCl2 added (negative control); B, 0.5 hour reaction; C, 1 hour reaction; D, 3
hour reaction; E, 4 hour reaction; F, 4 hour incubation of substrate without ribozyme C
and MgCl2.
The open arrow indicates the ribozyme C position and the solid arrows
indicate the two cleavage products.
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conditions, 28.4% cleavage of the starting substrate was
observed after 30 minutes, 41.4% after 1 hour, 64.6 % after
3 hours and 71.3% after 4 hours of incubation at 37°C. The
quantitation was determined by a BioVision imager and analy
zer system.

As demonstrated in Figure 9, complete cleavage

of the substrate, at a 1:1 substrate to ribozyme molar
ratio, was observed by 14 hours of incubation.
The anti-HIV-1 ribozymes turnover multiple substrates
We have examined the substrate turnover abilities of
two different ribozymes, ribozyme C (Fig. 12) and D (Fig.
13), which was designed with the same hammerhead motif as
ribozyme C. Ribozyme C was targeted to the gag gene and
ribozyme D to 5'LTR sequences,

In these experiments, the

amounts of substrate were kept constant while the ribozymes
were titrated to vary the substrate to ribozyme ratios from
1:1 to 50:1. By focusing on Figure 13 lane B, the substrate
to ribozyme ratio was 2:1 but more than 50% of the substrate
was cleaved. The turnover capacity of model IV ribozyme was
more pronounced with ribozyme D (Figure 14). Incubation of
the ribozymes with large molar excesses of substrate result
ed in catalytic turnover of greater than stoichiometric
amounts of substrate.
Testing of catalytic RNA in a Xenopus oocyte system.
Having shown that trans-acting ribozymes can function
effectively to cleave HIV-1 RNA in a cell-free system, we
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Figure 12. Ribozyme C titration versus gag substrate.
Ribozyme C (Figure 9) was titrated relative to a fixed
amount of 138 nts gag substrate (0.1 jiiM) such that substrate
to ribozyme molar ratios were: A, 1:1; B, 5:1; C, 10:1; D,
25:1; E, 50:1; F, 1:1 in the absence of MgCl2. The solid
arrows point to the cleavage products, the open arrow to the
ribozyme. Reactions were assayed under standard conditions
with 20 mM MgCl2.
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Figure 13. Ribozyme D titration versus 5'LTR substrate.
The anti-5'LTR ribozyme, ribozyme D, was titrated relative to a fixed amount
(0.1 /iM) of 5'LTR substrate (coordinate: 602-622) such that the target to ribozyme
ratios were: A, 1:1; B, 5:1; C, 10:1; D, 20:1; E, 50:1; F, 1:1, without MgCl2 added;
G, substrate alone, no ribozyme, plus MgCl2. Standard reaction conditions were
employed using 20mM MgCl2. Symbols: R indicates ribozyme D, S indicates 5'LTR
substrate and P indicates cleavage products which are 13nt and 8nt and ran together
on the gel.
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decided to test the ribozyme in a Xenoous oocyte for cata
lytic capabilities. The in vitro transcribed ribozyme C and
the 138 nucleotide HIV-1 gag substrate, both internally
labelled with af^PJUTP and capped at their 5

termini with

GpppG, were injected into 10 oocytes for each condition. The
injectedoocytes were incubated at room temperature for 3-4
hours and the total RNAs from the oocytes were analyzed for
the presence of the injected RNA's and/or their cleavage
products.

The substrate RNAs were still detectable, how

ever, slightly increased in size ( Fig. 14 lanes A, C,
D)

and

but the ribozymes were all degraded. No cleavage pro

ducts were observed in either lane C, where ribozyme and
substrate were injected together or lane D where ribozyme
and substrate were separately injected. As a positive con
trol, the in vitro transcribed substrate and ribozyme were
incubated for 4 hours at room temperature under the in vitro
cleavage reaction conditions (lane E).

Under these condi

tions, substantial cleavage of the target RNA took place.
Anti-HIV-1 ribozymes can function in a milieux of total
cellular RNAs.
There are many unknown variables influencing the effec
tive use of ribozymes in a living cell.

We decided that

some of these variables should be experimentally tested in
vitro before attempting to test ribozymes in a living cell
again.

To examine some of these, we synthesized a gene
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Figure 14. Determination of ribozyme C activity in Xenopus
oocytes.
Ribozyme C and the 138 nts gag substrate, both capped
with GpppG at the 5' end, were injected into Xenopus oo
cytes. The oocytes were incubated at room temperature for 34 hours and total RNA extracted. Lane: M, Hpa II-partially
digest pBR322 molecular weight markers; A, total RNA from 10
oocytes injected with only the capped gag substrate; B,
total RNA from 10 oocytes injected with only the capped
ribozyme; C, total RNA from 8 oocytes injected with capped
ribozyme C and capped substrate separately; D, total RNA
from 10 oocytes injected with capped ribozyme and capped
substrate premixed; E, in vitro cleavage reaction of the
capped ribozyme and capped substrate incubated at room
temperature for 4 hours with 20mM MgCl2 added; F, capped
substrate incubated at room temperature for 4 hours with
2 0mM MgCl2 added. The 5' and 3' cleavage products are indi
cated by the open arrows and the capped ribozyme C indicated
by the solid arrow.
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coding for a model IV ribozyme targeted to the translational
initiation region of the HIV-1 gag gene. This ribozyme (GAGHAM ribozyme) was initially cloned into a transcription
vector (pBKGAG-HAM) such that the in vitro

transcript re

sulted in a ribozyme with 70 non-HIV-1 complementary nucleo
tides derived from the vectorsequences to assess the in
fluence of non-complementary sequences on ribozyme activity
and efficiency.

Fifty of these are appended to the 5' end

of the ribozyme and 20 to the 3' end (Figure 15A).

These

extra nucleotides were derived from the poly linker sequen
ces of the vector. GAG-HAM ribozyme was characterized by the
in vitro cleavage reactions containing a 270 nucleotide gag
substrate incubated at the near optimal conditions of 50°C
and 20 mM MgCl2 (Fig. 15B). In this experiment GAG-HAM
concentrations were kept constant at 0.2 0 /xM but the sub
strate concentrations were varied from 1.3 nM to 0.13 /xM.
Using an AMBIS radioanalytical imaging system, the Km and
Vmax of the GAG-HAM ribozyme were determined from an EadieHofstee plot to be 210 nM and 0.83 nM/min., respectively
(Fig. 15C).
Subsequent to testing the ribozyme against a 270 nucle
otide substrate, GAG-HAM ribozyme was tested in vitro
against a longer 610 nucleotide gag RNA substrate and, in
addition to the substrate, varying amounts of total RNA
prepared from H9 lymphocytes either uninfected, or infected

VD

Figure 15. Characterization of GAG-HAM ribozyme.
A) GAG-HAM ribozyme is depicted here with 70 extra nucleotides from the polylinker
region of the pBluescript-KS(+) vector. The cleavage target of GAG-HAM ribozyme is in
the gag gene between nucleotides 805 and 806, just downstream of the AUG translational
initiation codon at 789-791.
B) GAG-HAM ribozyme concentrations were kept at a constant amount (0.2 /xM) for each
in vitro cleavage reaction. The substrate concentrations (an 175 base long in vitro
transcribed gag RNA, coordinate: 675 to 840 plus 10 bases of polylinker on the 5’ end)
were varied from 1.3 nM to 0.13 /iM. The cleavage reactions were incubated at 50°C and
20 mM MgCl2 for 4 hours. Lane: a, GAG-HAM ribozyme plus 0.13 /xM of substrate; b, GAGHAM ribozyme plus 65nM of substrate; c, GAG-HAM ribozyme plus 26 nM of substrate; d,
GAG-HAM ribozyme plus 13 nM of substrate; e, GAG-HAM ribozyme plus 1.3 nM of substrate;
f, GAG-HAM ribozyme plus 2.6 nM of substrate without MgCl2 added. The substrates (s),
5' cleavage products (p), and the ribozymes (r) are indicated.
C) Eadie-Hofstee plot of GAG-HAM ribozyme cleavage of an 175 base long gag substrate
RNA described in section b. The slope of the plot (correspond to -Km) is -220 and the
y-intercept (correspond to Vmax) is 0.83.
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with HIV-1, were added to the GAG-HAM ribozvme-qag substrate
reaction.
milieux.

This was done to simulate a complex in vivo
The results depicted in Figure 16 clearly demon

strate that the extra non-complementary flanking nucleotides
of the ribozyme did not inhibit cleavage of the target
sequence. In these experiments, GAG-HAM ribozyme was present
in molar excess over the targetsubstrate, and the incuba
tions were carried out at 37°C for 14 hours, conditions
which favor the complete cleavage of the target RNA.

It

should also be pointed out that the target itself was some
what degraded when incubated under reaction conditions in
the absence of ribozyme (2nd Lane, Figure 16).

By focusing

upon the amounts of the smaller cleavage product, which does
not appear to be subjected to the breakdown observed with
the input transcript and larger cleavage product, it can be
observed that inclusion of RNA from HIV-1 infected cells in
the reaction resulted in substrate competition for the ribozyme.

This is evidenced by reduced amounts of the smaller

cleavage product in the lanes containing the HIV-1 infected,
H-9 total cellular RNAs

(compare the (+) lanes to the (-)

lanes under conditions of a 2:1 ratio of ribozyme to input
gag transcript).

When the ratio of ribozyme to template was

increased 4 fold, there was no observable competition effect
(compare (+) and (-) lanes where the ribozyme to input gag
transcript ratio was 8:1).
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Figure 16. Analyses of GAG-HAM ribozyme in a complex milieux
of total RNA.
The experiment was designed to simulate an in vivo
milieux by adding total RNA from HIV-1 infected (+) or
uninfected (-) H9 lymphocytes. Two different ratios of
ribozyme to substrate (R:S) were utilized, 2:1 and 8:1 as
indicated (0.2 /iM:0.1 /iM and 0.8 /xM:0.1 /xM, respectively .
The amounts of total RNA from either the HIV-1 infected or
uninfected cells are indicated and range from 0.3 through
1.8 jxgms as indicated above each lane. The substrate (in
this case a 610 nts gag containing transcript containing
coordinates 675-1275 (plus 10 bases of polylinker on the 5'
end))
is indicated (S), as are the cleavage products (P)
and the ribozyme (R). The larger cleavage product is 469
nts and derives 3' of the cleavage site, and the smaller
product is 141 nts. and derives 5' of the cleavage site.
The reactions were performed under standard conditions with
20 mM MgCl2.
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HIV-1 infection of H9 lymphocytic cells containing in vitro
synthesized anti-gag ribozyme (Transient ribozyme protection
assay).
The therapeutic use of ribozymes in a cellular environ
ment is one of our goals. A fast way of testing ribozyme in
a cellular environment is by delivering preformed ribozyme
to the cells. We reasoned that small RNA molecules (120-150
nucleotides long) could be taken up directly by the cell.
Northern analysis of total RNAs from the H9 lymphocytes that
were incubated in ribozyme containing serum-free media
confirmed that full sized ribozyme were detectable up to 1
hour after incubation (Fig. 17A). The 5 hour sample showed
that ribozymes were either processed into larger or smaller
products. In the next experiment, GAG-HAM ribozyme treated
H9 cells were challenged with HIV-1,

As a control anti-

herpes simplex virus (anti-HSV) ribozyme of the same length
was used as a negative non-specific control for the second
and third experiments. Using syncytia formation as an assay
for viral infectivity (Zaia et al., 1988), the percent
inhibitions of viral infection average around 50 for experi
ments with ribozyme concentrations greater than 10 /xM (Table
1). In experiment #2, dosage effect of GAG-HAM ribozyme
inhibition of viral infection was demonstrated. However, the
dosage effect of anti-HSV ribozyme was also demonstrated but
to a lesser extent (Table 1). To verify indirectly that

03
U1

Figure 17. Transient ribozyme uptake and protection against HIV-1 infection.
A) Northern analysis of total RNA from H9 lymphocytes pre-treated with polybrene and
incubated in serum free media containing IOOjxM of GAG-HAM ribozyme. Two different
samples, 1 hour and 5 hours post-incubation, were analyzed. The arrow indicates the
position of GAG-HAM ribozyme control lane that is overexposed (not shown).
B) Polymerase chain reaction (PCR) was utilize to analyze the level of HIV-1 gag and
nef RNA from total RNA isolated from H9 lymphocytes challenged with HIV-1 (Table 1,
experiment #3a). The polybrene pre-treated H9 lymphocytes were allowed to take up GAGHAM ribozyme or a non-specific anti-HSV ribozyme for one hour before being challenged
with the virus.
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Table 1. Inhibition of HIV-1 mediated giant cell (syncytia)
formation by exogenously delivered GAG-HAM ribozymes in H9
lymphocytes. a
Concentration of
ribozvme in ttM.

Percent inhibition6 of
Anti-HSV ribozvme0
GAG-HAM ribozvme

Experiment #1:
10
50
100

N.D.
N.D.
N.D.

42.4%
64.7
67.1

Experiment #2:
1
10
100

6.1
10.9
35.0

8.6
40.6
52.0

Experiment # 3 a:
10
100

17.6
18.1

54.7
51.7

Experiment #3b:
10
100

N.D
N.D.

51.5
58.3

Approximately 2 x 106 H9 cells, pre-treated with polybrene,
were incubated in serum free media containing free ribozyme
at the indicated concentration for one hour at 37oC. These
cells were then challenged with HIV-1. The positive control
were subjected to the similar treatments excepted the in
cubation at 37oC for one hour was done in serum free media
without any ribozyme.
bThe percent inhibitions were calculated from the number of
giant cells (syncytia) formed at day 7 post-infection as a
percent of the positive control.
cThe anti-HSV ribozyme contained flanking sequences com
plementary to herpes simplex virus(HSV) and was of the same
size as GAG-HAM ribozyme.
N.D.= not determined.
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ribozyme did mediate a reduction in the gag mRNA level, we
used polymerase chain reaction (PCR) assay to amplify two
different sections of total RNA from the 100 /uM samples from
experiment #3.

Relative reductions of gag mRNA and nef mRNA

levels from anti-gag ribozyme treated H9 lymphocytes com
pared to the anti-HSV ribozyme treated H9 lymphocytes were
demonstrated (Fig. 17B) .
Expression of an active anti-gag ribozyme in transfected
CD4+ HeLa cells.
As a therapeutic agent, the continuous presence of
biologically active ribozyme in the cell is desirable. An
initial step for achieving this goal is the expression of a
functional ribozyme in living cells.

To achieve this, we

synthesized and cloned the GAG-HAM ribozyme in a eukaryotic
expression vector, pHBAPr-l-gpt. This vector contains the
human B-actin promoter and SV-40 late transcriptional ter
mination and poly adenylation signals (Gunning et al.,
1987).

The resultant plasmid, pPC-RAG12 (Fig. 18A), was

transfected into CD4+ HeLa cells by a lipid mediated trans
fection procedure called lipofection (Feigner et al., 1987)
and stably transfected clones were selected for the expres
sion of E. coli xanthine-guanine phosphoribozyltransferase.
The transformants that survived selection were screened
using the PCR assay for the detection of intracellular
expressed ribozyme. The first strand primer was
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Figure 18. Intracellular expression of GAG-HAM ribozyme in
HeLa CD4+ cells.
A) The eukaryotic expression vector for intracellular
expression of GAG-HAM ribozyme is depicted (pPC-RAG12) The
ribozyme gene is under the control of human B-actin promotor
and contains a copy of SV-40 poly adenylation signal.
B) PCR amplification of GAG-HAM ribozyme from total RNA
from different clones lanes A, C and D and from a pooled
clone lane B.
C) The expression of GAG-HAM ribozyme in a HeLa CD4+
clone was shown as a broad band centered at ca. 450 nts. The
analyses were done on poly (A)+ RNA from a Hela CD4+ clone
expressing ribozyme D from the human B-actin promoter, (lane
A). RNA from the untransformed HeLa CD4+ parent line was
electrophoresed in lane B. M is the HpaII-digested pBR322
molecular weight markers.
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complementary to SV40 sequences 3' to the ribozyme coding
region, but upstream of the polyadenylation signal. The
other primer was in the 5' end of the ribozyme gene and the
same polarity as the transcribed RNA.

The results demon

strated the expression of GAG-HAM ribozyme in each of the
assayed clones (Fig. 18B lanes A, C and D) and in the pooled
colonies (lane B).

A northern blot analysis was also per

formed on poly (A)+ RNA isolated from one of the expressing
clones to characterize the intracellular expressed GAG-HAM
ribozyme.

A rather diffuse hybridizing band centered at

approximately 450 nucleotides was observed (Fig. 18C),
suggesting that approximately 200-300 poly adenosines are
added to the primary transcripts.
To determine whether or not the expressed GAG-HAM
ribozyme transcripts with the extra nucleotides added, were
catalytically active, varying amounts of total RNA (0.2 ugm,
1.0 ugm and 5.0 ugms) from one of the clones were tested in
an in vitro cleavage reaction (Fig. 19A). The substrate used
was a 172 base long in vitro transcribed gag RNA, internally
labelled with a-32P UTP.

At the highest total RNA concen

tration tested (5/igms) , the 5' cleavage product was detected
(lane C).
Determination of cytotoxicity in HeLa CD4+ expressing GAGHAM ribozyme.
One of the potential problems with a constitutively

tv)

Figure 19. A) Cleavage of in vitro transcribed gag substrate by intracellularly
expressed GAG-HAH ribozyme and B) growth characteristic of GAG-HAM ribozyme expressing
HeLa CD4 cells.
A) Total RNA from a HeLa CD4+ clone expressing GAG-HAM ribozyme was tested for
cleavage activity.
A 175 nts long in vitro transcribed gag substrate (0.05 /iM, large
solid arrow, lane A), was mixed with in vitro transcribed GAG-HAM ribozyme (lane B) or
5 /xgms(C), 1/igm (D) , 0.2jLtgm (E) of total RNA from the ribozyme expressing HeLa clone.
The in vitro cleavage reaction conditions were standard in the presence of 20 mM MgCl2.
The bracketed bands are spontaneous degradation products of the UTP32 labelled sub
strate. As can be seen in lane B, these are substrates for the ribozyme since the in
vitro transcribed molecules completely cleave these to smaller products (not seen in
this picture). The small arrow indicates the 5' cleavage product which is 141 nts in
length. The 3' product of 36 nts is not shown. The large open arrow indicates the
electrophoretic position of the in vitro produced ribozyme D.
B) The 9-day growth curve of a GAG-HAM ribozyme expressing HeLa CD4 clone as compared
to the parental HeLa CD4 cells.
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expressed foreign gene is its possible deleterious effect on
cell viability. We used a short-term growth analysis as a
measurement of cell viability by comparing the growth rate
of the GAG-HAM ribozyme expressing HeLa CD4 cell line and
the untransformed parental HeLa CD4 cell line (Fig. 19B).
The average doubling time over a 9-day

period was 24.2

hours for parental cells and 23.2 hours for ribozyme-containing cells (Table 2).
viability

Over the same 9-day period, cell

wasgreater than 99% as measured by trypan blue

exclusion for both cell lines (transformed and untrans
formed) . The plating efficiencies, determined at day 1 postseeding, were greater than 90% for both cell lines and no
morphological differences were detected (Table 2). After
more than 15 months in culture, the ribozyme expressing cell
line showed no signs of cytotoxicity.
HIV-1 infection of HeLa CD4 expressing an active anti-gag
ribozyme.
To test the anti-gag ribozyme for its ability to cleave
viral RNA in an intracellular environment, cells expressing
the ribozyme were challenged with HIV-1. As a positive
control, parental HeLa CD4 cells were used. Quantitative
determination of soluble p24 antigen (gag protein) was
performed seven days post-infection (Table 2). The p24
concentrations were markedly reduced in the cloned transfor
mants (0.14 ng/ml) and pooled transformants (0.23 ng/ml)

Table 2. Summary of cellular characteristics of GAG-HAM ribozyme express
ing HeLa CD4 cells and the soluble p24 antigen levels 7 days post HIV-1
infection.
Parental
HeLa CD4 cells
Growth rate®

24.2 hours

Ribozvme expressing HeLa CD4 cells
(single clone)
(pooled clone)
23.1 hour

N.D.

Plating efficiency6

>90%

>90%

N.D.

Cell viability0

>99%

>99%

N.D.

p24 antigen leveld

>10 ng/ml

0.14 ng/ml

0.23 ng/ml

*The average doubling time over a 9 day period of each cell line were
determined by counting cells on a hemocytometer at day 1,2,5,and 9 postseeding. The cells growing in 60 mm plates were trypsinized and pelleted.
The cell pellets were resuspended in 0.25- 0.5 ml of Hepes buffered saline
solution and diluted 2 or 5 fold for counting. Cell counts were carried
out in duplicate for each counting period.
bPlating efficiencies were determined from cells counted on day 1 postseeding.
°Aliquots of cells from each counting period were assayed for viability by
trypan blue exclusion.
dThe levels of HIV-1 excreted p24 gag protein into the cell media were
determined by DuPont's HIV p24 Core Profile ELISA kit.
N.D. = not determined.
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[100 times as compared to the untransformed parental cells
(>10 ng/ml)].
Additionally, viral gag RNA levels were measured from
total RNA using PCR analysis. Three primers were utilized to
determine the relative amounts of intact viral gag RNA.
GAG1, a 22 base long deoxyribonucleotide, is the firststrand primer complementary to HIV-1 RNA, located within the
GAG region 200 nucleotides downstream of the expected cut
site (Fig. 20). This primer was used to make the first
strand c-DNA from the viral RNA by reverse transcriptase.
GAG2 (a 25 base long deoxyribonucleotide) and LTR1 (a 25
base long deoxyribonucleotide) are second-strand primers of
the same polarity as the viral RNA. The LTR1 primer is 240
nucleotides 5' to the cleavage site and selectively amplif
ied the uncleaved RNA resulting in a 480 nucleotide product,
while the GAG2 primer is complementary to 15 nucleotides 3'
of the cleavage site and amplified both cleaved and un
cleaved RNA to give a 200 nucleotide fragment. The rationale
for this experiment is as follows: If the ribozyme mediated
cleavage occurred, the larger PCR product, a 480-nt fragment
extending from LTR1- GAG1, should be reduced relative to the
smaller product, a 200-nt fragment extending from GAG2-GAG1.
In the absence of cleavage, the two products would be more
or less equivalent in amount. The results showed that both
the amplified viral fragments (480 and 200 nucleotides) from

VO
'vl

Figure 20. GAG-HAM ribozyme mediated cleavage of gag RNA after challenge with HIV-1.
The relative positions of different primers with respect to the cleavage site within
the gag RNA is depicted. Two amplifications of the gag RNA from each samples were done.
The 200 nts products represent the level of both the cleaved and uncleaved gag RNA. The
480 nts products represent only the uncleavaed gag RNA. Lane: A, untransformed HeLa CD4
parental cells; B, cloned cell line transformed with anti-gag ribozyme; C, pooled
clones transformed with the anti-gag ribozyme; D, PCR contamination control.
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untransformed parental HeLa CD4 cells were similar in amount
as expected (Fig. 20, A lanes). In contrast, RNA from the
cloned cells expressing the ribozyme (B lanes) contained
significantly less of the larger, 480-nt species, while the
same 480 nt. product from the pooled clones (C lanes) was
almost undetectable. The smaller 200 nt fragment from both
ribozyme expressing samples was also reduced relative to the
parental HeLa CD4+ cells (compare lanes B and C to lane A).
In vitro transcribed ribozyme (preformed ribozyme) delivery
systems.
The testing of ribozymes in a living cell by delivering
in vitro transcribed RNAs to the cells was initially per
formed by challenging the cell with HIV-1 as described above
(Fig. 17 and Table 1). The presence of full sized ribozyme
was detected up to 1 hour post-uptake (Fig. 17A). To in
crease the uptake of RNA by the cells, two different techni
ques are available: 1) by micro injecting RNA directly into
the cell or 2) by facilitating the cellular uptake of the
RNA. Micro injecting RNA is not practical if ribozyme is to
be used as a therapeutic agent, therefore a facilitated
cellular uptake of RNA was studied.

The facilitated cel

lular uptake system tested was a lipid-mediated delivery
system (liposome)

(Knight, 1981; Ostro, 1983) in collabora

tion with a biotechnology company Vestar Inc., San Dimas,
Cal.

100
In vitro transcribed RNAs, internally labelled with
a[32P]-UTP, were packaged into liposomes by Vestar.

The

packaged ribozymes and free ribozymes were added to the
growth media of the H9 lymphocytes for uptake by the cells.
After 1, 3, 24 and 40 hours of incubation in ribozyme con
taining media, the cells were harvested and total RNAs
analyzed by gel electrophoresis. The stability of the de
livered RNA was increased by capping the synthetic RNA with
a cap analog which was demonstrated not to interfere with
the cleavage activity (Fig. 9, lanes B2 and C2). The results
suggested that the liposome encapsulation protected the
ribozymes up to 40 hours (Fig. 21, 1 lanes) and resulted in
increasing intracellular ribozyme content up to 40 hours. In
contrast, no full sized ribozymes were detected even at the
1 hour time point in the free ribozyme experiment (Fig. 21,
f lanes).

However, ribozymes from both conditions were

processed into larger products, double bands on the top of
the figure, and a smaller product approximately 76 nt. long.
The intracellular processing of the injected RNA was more
pronounced in the free ribozyme (at the one hour time point)
as compared to the liposome delivered system even at the 40
hour time point.
To confirm that the larger products seen by delivering
labelled ribozymes were not due to the recycling of the
phosphate, a northern analysis was performed for total
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Figure 21. Characterizations of liposome delivered RNA.
A) GAG-HAM ribozyme was encapsulated by Vestar, Inc., San Dimas, Cal. The encapsulated ribozymes (1) and free ribozymes (f) both internally labelled with
were added
to the growth media of H9 lymphocytes for the indicated times. The total RNA extracted
and analyzed on denaturing polyacrylamide gels. The arrow represents the position of
GAG-HAM ribozyme.
B) The encapsulated ribozymes and free ribozymes, both unlabelled, were delivery to
H9 lymphocytes. The total RNAs from the cells were extracted and analyzed on a 2%
agarose formaldehyde gel. Lane: A, untreated H9 cells; B, encapsulated ribozyme treated
cells after 24 hours of incubation; C, encapsulated ribozyme treated cells after 48
hours of incubation; D, free ribozyme treated cells after 1 hour incubation; E, free
ribozyme treated cells after 3 hours incubation. The northern blot was probed with a
ribozyme specific oligonucleotide probe. The solid arrow represents the position of the
in vitro transcribed ribozyme.
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RNAs from unlabelled delivered ribozymes (Fig. 2IB). The
diffuse band at the top of the 2 % formaldehyde-agarose gel,
hybridized to the ribozyme specific probe, and this sug
gested that the larger products contained ribozyme specific
sequences. This diffuse band was seen in

the free ribozyme

experiment when ribozyme was incubated for 1 hour (lane D)
and 3 hours (lane E). In the encapsulated ribozyme experi
ment, the band was not detectable until the cells were
incubated with encapsulated ribozyme for at least 24 (lane
B) and 48 hours (lane C).
Design and testing of DNA-RNA hybrid ribozyme target to HIV1 gag gene.
Another potential class of exogenously delivered ribo
zyme is the chemically synthesized RNA. However, the chemis
try and the cost of synthesizing the RNA are the limiting
factor for exploring the potential use of chemically syn
thesized RNA. To overcome some of the limitations along with
enhancing the stability of the molecule, we have designed
and synthesized, in collaboration with the Beckman Institute
of City of Hope's chemistry lab, a hybrid DNA-RNA ribozyme
(Fig. 22a), that contains the less stable and more expensive
ribonucleotides only at the catalytic center. The hybrid
DNA-RNA ribozyme is targeted to the same site as that of the
GAG-HAM ribozyme and was shown to have biological activity,
capable of cleaving in vitro transcribed substrate RNAs

M
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Figure 22. The design and testing of synthetic DNA-RNA-DNA (DRD) ribozyme.
A) The design of DNA-RNA-DNA ribozyme is depicted. All the essential bases that
comprise the catalytic center were synthesized with ribonucleotides (underlined). The
flanking regions and stem I were synthesized with deoxyribonucleotides.
B) The presence of ribonucleotides was checked by digestion with RNase A. The DRD
ribozyme and its DNA control were 5' end labelled with 32P. The arrow represents the
cleavage product of the DRD and not the DNA counterpart.
C) The DRD ribozyme was tested for its cleavage activity by incubating with two
different sizes of in vitro transcribed gag RNAs. The 610 base long gag RNA (described
in legend to Fig. 16) and the 175 base long gag RNA (described in legend to Fig. 15)
were incubated with DRD ribozyme from two purification fractions (#1 and #2) and the
deoxy control (D) . DRD lane: A) DRD ribozyme from a purification fraction #1 plus the
610 base long substrate, B) DRD ribozyme from a purification fraction #1 plus the 175
base long substrate; C) DRD ribozyme from a purification fraction #2 plus the 175 base
long substrate. D lane: A) Deoxy control incubated with the 175 base long substrate; B)
deoxy control incubated with the 610 base long substrate; and S) the 175 base long
substrate alone. The open arrows indicate the substrate positions and the solid arrow
indicates the cleavage products.
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(Fig. 22C). The digestion of the hybrid molecule by endoribonuclease A was used to confirmed the presence of the
ribonucleotides in the molecules (Fig. 22b).
Anti-lacZ ribozymes and their expression in Yeast.
We have initiated the use of yeast S. cerevisiae as a
model for studying intracellular expression and activity of
ribozyme. Before expressing ribozymes in yeast, two antilacz ribozymes, BETA-HAM and GAL-HAM, were tested for their
in vitro cleavage activity of in vitro transcribed 180
nucleotide long substrates. BETA-HAM ribozyme is targeted to
the E. Coli lacZ gene at the GUC nucleotide 40 bases down
stream of its natural start codon (Fig. 23).

GAL-HAM ribo-

zyme is also targeted to the same GUC and the only dif
ference between the two ribozymes is that the flanking
sequences of GAL-HAM ribozyme at stem I contains a one base
pair mismatch of U-U two bases 3
23) .

of the cleavage site (Fig.

BETA-HAM and GAL-HAM ribozymes were incubated with the

substrates at 1:0.45 and 1:0.71 ratios of substrate to
ribozyme respectively, in 20 mM MgCl2

for 5.5 hours at two

separate temperatures (Fig. 23). The two temperatures were
30°C, an optimal temperature for yeast growth, and 50°C, an
optimal temperature for a characterized ribozyme's cleavage
activity (Uhlenbeck, 1987). Using an AMBIS radio-analytical
imaging system, the cleavage activities of the BETA-HAM
ribozyme were determined to be higher than GAL-HAM's at both

107

Figure 23. Characterization of two different anti-lacZ
ribozymes.
The sequence of the GAL-HAM ribozyme containing the U:U
mismatch at the starred position is shown. A second ribozyme
without the mismatch is called BETA-HAM. The two ribozymes,
GAL-HAM (U) and BETA-HAM (A), were assayed for their cleav
age activity at two indicated temperatures. The substrate
was an 180 base long the in vitro transcribed lacZ RNA from
pGEM3Z (Promega) linearized with PyuII. The solid arrows
indicate the position of the two cleavage products and the
open arrow represents the position of the two ribozymes.
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temperatures, approximately 3.5 x greater at 30°C and 1.2 x
greater at 50°C (compare lanes U to A at both temperatures) .
The same two ribozymes were each cloned into two dif
ferent yeast shuttle plasmids, both under the control of
GAL1 promotor, which is a galactose inducible promotor. The
two shuttle vectors were chosen to control the intracellular
plasmid copy number with the 2 micron plasmid as a high copy
number plasmid (pYGR2PC) and the CEN3-ARS1 plasmid as a
single copy number plasmid (pYGRCPC)

(Fig. 6).

The GAL1

promotor is repressed when yeast utilizes glucose as the
carbon source butupon switching of the carbon source to
galactose the transcription from GAL1 promotor is induced by
over a 100 fold. The plasmids were transformed into yeast
strain JM43. After growth in appropriate media to select for
the presence of the plasmids, the carbon source was switched
from glucose to galactose. Northern analysis of total RNAs
from uninduced (glu) and induced (gal) clones containing the
2 micron plasmid (lanes 1) and the CEN3-ARS1 plasmid (lanes
2)

(Fig. 24A) confirmed that the ribozymes were expressed

and were under the control of the galactose inducible pro
moter.
The ribozymes from the induced clones were tested for
their catalytic activity by incubating 10 ugms of total RNA
from each vector type with the 180 nucleotide long in vitro
transcribed substrate (Fig. 24B). The 5' cleavage product of
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the expected size

was detected when incubated with the

total RNA from the induced 2 micron plasmid (lane D) but not
in the total RNA from uninduced yeast not expressing ribozyme (lane A) or total RNA from the induced CEN3-ARS1 plas
mid (lane C). The in vitro transcribed GAL-HAM ribozyme was
used as positive control in lane B.

Ill

Figure 24. The characterization of anti-lacZ ribozymes A)
northern analysis and B) in vitro cleavage reaction.
A) Two different carbon sources (glucose and galactose)
were used to grow yeast cells containing the GAL-HAM ribozyme. The two different clones analyzed contain 1) a single
copy number plasmid, pYGRCPC (lanes 1) and 2) a high copy
number plasmid, pYGR2PC (lanes 2). The total RNAs were
analyzed on 4% polyacrylamide/7M urea gel. The arrow indi
cates the position of intracellular expressed GAL-HAM ribozyme.
B) The yeast expressed GAL-HAM ribozyme was tested for
cleavage activity by incubating total RNA extracted from the
two different clones grown under galactose induced condi
tions with the 180 base long lacZ RNA (described in legend
to Figure 23). The cleavage reactions were incubated at 30°C
for 14 hours with 20mM MgCl2. Lane: A, 10 /ig of total RNA
from cells not expressing ribozyme; B, in vitro transcribed
GAL-HAM ribozyme for positive control without any total RNA
added; C, 10 /xg of total RNA from cells containing single
copy number plasmids; D, 10 fig of total RNA from cells
containing high copy number plasmids. The small arrows
depict the 5' cleavage product and the large arrow the 3'
cleavage product.
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DISCUSSION
In vitro experiments
New modalities for the therapeutic treatment of HIV-1
infection have received considerable attention.

The present

studies are directed at developing catalytic RNAs, or ribozymes, specifically targeted to HIV-1 sequences for use as
anti-viral agents.

The molecules described in these studies

are targeted to HIV-1 sequences by complementary base pair
ing and effect site-specific cleavage of the target without
themselves being altered.

Using the "hammerhead” catalytic

centers common to several plant viroid and virusoid auto
cleaving RNAs (Buzayan et al., 1986; Hutchins et al., 1986;
Prody et al., 1986; Forster and Symons, 1987a), we have
designed two different classes of anti-HIV-1 ribozymes.
Model I ribozymes, represented by ribozymes A (Fig. 8) and B
(Fig. 9), utilize sequences within the HIV-1 genome to
comprise part of the ribozyme catalytic center.

The

cleavage reaction takes place in the HIV-1 strand after a
GUN sequence.

To our knowledge, these are the first ex

amples demonstrating the feasibility of converting a noncatalytic, naturally occurring sequence into part of the
active site of a ribozyme.
lizing this approach though.

There are constraints to utiThe first sequence we chose to

target, lies within the 5* portion of the gag gene of HIV1. This target worked poorly since it is probably incapable
of forming a stem III. Hammerhead catalytic RNAs with an
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unstable stem III occur in nature in the newt satellite RNA
autocleavage domain and in the avocado sunblotch viroid plus
strand (Hutchins et al., 1986; Forster and Symons, 1987b).
These RNAs have been proposed to fold into an active confor
mation by the association of two identical centers forming a
more stable dimeric catalytic center (Forster et al, 1988;
Sheldon and Symons, 1989a). The formation of a dimeric
catalytic center is less likely for a large substrate, such
as the one used in testing ribozyme A, because of other
competing folding patterns.
The catalytic efficiencies of reactions utilizing model
I type ribozyme will depend upon both the rate of intermolecular hybrid formation and the rate of achieving active
site conformations. In designing ribozyme B, we carefully
screened all the possible GAAAC containing regions in HIV-1
for one in which the proper juxtaposition of this element to
the cleavage site GUN could be predicted. The second site we
chose to target, predictably allowed formation of all the
required stems. The stability is reflected by the higher
cleavage activity of ribozyme B (Fig. 9, B lanes ) compared
to ribozyme A (Fig. 8). However, other sites in HIV-1 are
less promising with respect to forming a catalytically
active structure. Nonetheless, we have clearly demonstrated
the feasibility of using this approach to direct site spec
ific cleavage of a template within which the required
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elements can be identified. A possible advantage of this
type of ribozyme is its simplicity,

Aside from the base

pairing sequences, there is a requirement for only seven
other bases which make up part of the active site. In the
future, it will be important to evaluate this model of
catalytic RNA in an intracellular environment.
The work of Haseloff and Gerlach (1988) has led to the
design of a new class of ribozymes (model IV) which can
target any GUN triplet.

Their design incorporates all of

the conserved, catalytic center nucleotides, with the excep
tion of the GUN cleavage site, into one strand.

There are

literally hundreds of susceptible targets in a genome as
large as that of HIV-1,

Thus, the choice of target is not

limited to identifying a pentameric or heptameric sequence,
but rather is dictated by the accessibility of base-pairing,
and the strategic location of the target to destroy its
biological function, discussed below. The direct comparison
of model I (Ribozyme B) and model IV (Ribozyme C) catalysts
demonstrated that ribozyme C is capable of processing more
substrate than ribozyme B (Fig 9).

The increase in the

catalytic activity of ribozyme C is a reflection of the
stability and the ease of the formation of stem III. The
flexibility in the choice of target sites, the potential for
greater stability of stem III, and the capability of pro
cessing greater amounts of substrate contributed to our
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decision to utilize a model IV ribozyme in all our subse
quent studies. We have tested this class of ribozyme by
targeting two different sites within the qaa gene of HIV-1
(ribozyme C, GAG-HAM ribozyme, and DNA-RNA ribozyme), a
single site within the 5'LTR regions (Ribozyme D) and two
anti-lacZ ribozyraes for the yeast system (GAL-HAM and BETAHAM) .
Our target choices were based upon several criteria. In
E. coli. antisense RNAs targeted to lacZ mRNA were demons
trated to yield maximal inhibition of B-galactosidase syn
thesis when targeted to the regions of mRNA corresponding to
the lacZ ribosome binding sites and/or the 5'-coding sequen
ces (Daugherty et al., 1989). In eukaryotes, there is no
direct evidence that antisense RNA acts by interfering with
the translational machinery in vivo, even though hybridarrest of in vitro translation has become a standard labora
tory procedure for matching proteins with their coding
sequences in mRNA.

However, targets such as the regions

adjoining a translational initiation codon, mRNA cap and
splicing donor and acceptor sites have been shown to be
accessible to synthetic oligonucleotide-meditated antisense inhibition of function in cultured eukaryotic cells
(Goodchild et al., 1988? Zaia et al., 1988).

These sites

are known to be accessible to protein binding and perhaps
anti-sense agents, as well. Using a simple, secondary
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structure prediction method such as that of Zuker and Stiegler (1981), the potential for target sites forming secondary
structures, thereby preventing ribozyme binding, can be
assessed. Besides the possibility of being more accessible
to base pairing in vivo, these sites encode important regu
latory functions which enhance mRNA stability or provide
signals for pre-mRNA processing and translational initia
tion. Taking into consideration the natural preference for
GUC at the ribozyme cleavage site (Forster and Symons 1987b;
Haseloff and Gerlach, 1988), occurrences of this triplet
within regulatory regions are sought as potential,
preferred, target sites.
After we designed the model IV ribozyme used in this
study, it was subsequently shown that a further reduction
from 13 to 11 bases within the catalytic center was possible
(Koizumi et al., 1989). The conserved bases GAAAC and GUN
can be reduced to GAAAX1 and X2UN, when

and X2 nucleotides

can form a Watson-Crick base pair. This finding substantial
ly expands the possible target sites of the model IV ribo
zyme against HIV-1 from 11 sites (see figure 7) to 99 sites.
The less restrictive target requirements also make the model
I ribozyme more versatile with the possibility of selective
targeting of important regulatory regions.

Furthermore, the

number of target sites for model IV ribozymes can now be
increased to accommodate any occurrences of UC, UA, or UU

118
di-nucleotides, which makes virtually all RNAs potential
targets for ribozyme mediated inhibition. We have incor
porated these findings in our designing of other ribozymes
not presented in this dissertation.
The hammerhead ribozyme has been demonstrated to cleave
precisely after the XUN nucleotide as presented in Figure 9.
In our hands these ribozymes, specifically ribozyme C, do
cleave the substrate RNAs after the XUN (GUN) nucleotide as
expected.

However, we observed that a minority of the

cleavages occurred after the GU nucleotide, one nucleotide
5* of the expected site (Fig. 9, ribozyme C and Fig. 11A). A
similar, unexpected cleavage site has also been reported by
others (Sheldon and Symons, 1989b). The discovery of this
unexpected cleavage site does not jeopardize the specificity
or the catalytic potential of these ribozymes since the
secondary cleavage site is only one nucleotide removed from
the primary site.

Furthermore, it is unclear whether or not

experimental factors such as flanking sequence, temperature,
etc.

have an influence on such secondary cleavages.
The cleavage reactions in most of this dissertation

were incubated at 37°C, the physiological temperature for
mammalian cell growth. The optimal temperature for ribozyme
mediated cleavage reactions will depend upon factors such as
differences in the length of the flanking regions, the
stability of stem III and the length of the substrate
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(potential competing secondary structure). Uhlenbeck (1987)
has determined an optimal temperature for cleavage activity
of a 13 base long model I ribozyme to be at 50°C. The sub
strate of this 13 base long ribozyme was a 24 base long RNA.
We have determined the optimal temperatures for ribozymes B
and C to be at 45°C for the cleavage of a 138 base long sub
strate RNA (Fig. 10). For each new ribozyme, the optimal
temperature for its catalytic activity will have to be
determined individually. However, the cleavage activities of
both ribozymes B and C, representing model I and IV designs,
were substantial at the physiological temperature (37°C)
(Fig. 10), the temperature which anti-HIV-1 ribozymes will
ultimately be used.
One of the potential advantages of using catalytic RNAs
as antisense agents is their ability to cleave multiple
substrates. Uhlenbeck (1987) demonstrated that a transacting hammerhead ribozyme is capable of multiple turnover
of substrate RNA, Kcat=0.5 per minute. In this study, the
substrate was a 24 nucleotide long RNA.

In our hands, the

cleavage efficiencies of trans-acting hammerhead ribozymes
are dependent on the substrate size. Initially, ribozyme D,
tested with a 240 nucleotide long in vitro transcribed RNA
at a 1:1 molar ratio of substrate to ribozyme, was demons
trated to function very inefficiently with less than 10
percent cleavage after 12 hours of incubation at 37°C (data
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not shown). When the substrate size was switched from

240

to 21 nucleotides, over 90 percent cleavage of the substrate
RNA was observed even at a 50:1 molar ratio of substrate to
ribozyme

(Fig. 13). However, the size dependence of cata

lytic activity is less pronounced at other target sites as
demonstrated by the GAG-HAM ribozyme discussed below. We
have also demonstrated that ribozyme C can turn over greater
than stoichiometric amounts of a relatively long substrate,
a 138 nucleotide long RNA (Fig. 12).
The true measure of the usefulness of a ribozyme as an
anti-viral agent will be the ability of such a molecule to
bind and efficiently cleave large transcripts, such as
mRNAs, or in the present case, the full length HIV-1 genome.
The 610 nucleotide gag transcript depicted in figure 16, was
readily cleaved by our GAG-HAM ribozyme, making this one of
the longest successfully cleaved targets reported to date.
It will be important to demonstrate that even longer RNAs
than this can be targeted and efficiently cleaved. In these
same experiments, we also identified a competitive inhibi
tion of cleavage by RNA from HIV-1 infected cells. Such an
inhibition was not apparent in experiments in which unin
fected total cellular RNA was added to the cleavage reac
tions.

We interpret these results to indicate that the

longer target sequences from HIV-1 in the RNA milieux were
effective in at least binding ribozyme, suggesting a
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selectivity for substrate interactions. The selectivity of
the ribozyme for the substrate is very important, and should
minimize any cytotoxicity that can occur by the promiscuous
binding and cleavage of non-targeted cellular RNAs.
In vivo experiments
A rapid assay for testing the usefulness of ribozymes
as anti-viral agents is the "transient" ribozyme experiment
(Table 1). H9 lymphocytes capable of HIV-1 infection were
allowed to passively take up GAG-HAM ribozyme by pre-incubation of the cells in polybrene, followed by incubation in
serum free media containing the ribozyme. The presence of
RNA, associated with the cells, was seen for up to 5 hours
post-incubation (Fig. 17A), suggesting some cellular pathway
for uptake of small RNAs. Cellular pathways for the uptake
of DNA oligos have been described (Loke et al., 1989? Yakubov et al., 1989). An 80 kDa protein has been proposed to
mediate cellular uptake of oligonucleotides in a size-dependent manner compatible with receptor-mediated endocytosis
(Loke et al., 1989). In that study, the uptake of deoxyoligonucleotides was inhibited by the addition of tRNA to
the media suggesting competition by the tRNA for the trans
porter. In the experiments described above, the GAG-HAM
ribozyme treated cells contained reduced amounts of HIV-1
mRNA as compared with the anti-HSV ribozyme treated cells
(Fig. 17B). A similar, but less dramatic reduction in nef
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mRNA levels in the GAG-HAM ribozyme treated cells suggests
that the ribozyme renders some protection to the cells,
leading to a reduced viral load. Our inability to amplify
viral RNA across the cleavage site suggests that the viral
protection was possibly due to ribozyme-mediated cleavage
activity. However, the exact mechanism(s) for the protection
is yet to be determined.
The magnitude of HIV-1 infection was also determined by
multi-nucleated syncytia formation (Zaia et al., 1988). The
syncytia formation seemed to plateau at an extracellular
concentration of 10 /iM added ribozyme (Table 1) . The in
crease in the extracellular concentrations, perhaps, was not
reflected by the increase in the intracellular concentra
tions due to a possible saturation of the uptake machinery
at 10 /xM of ribozyme in the media. The uptake of oligodeoxyribonucleotide has been shown to be most efficient at
lower oligomer concentration, <l/xM, and over a broad con
centration range (0.01-100 /iM) of oligodeoxy-nucleotide in
the media. A plateauing effect of cellular uptake a within
2-hour incubation period was demonstrated (Yakubov et al.,
1989). Whether the ribonucleotide uptake kinetics are
similar to that of their deoxy counterparts is unclear.
Nevertheless, GAG-HAM ribozyme was taken up by the cells
which rendered them partially resistant to HIV-1 infection.
Protection by this ribozyme may be further enhanced by
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boosting the intracellular concentration of ribozyme either
by a facilitated delivery system or high level intracellular
expression.
As a prelude to experiments in which an intracellularly
expressed ribozyme can be used to prevent or treat HIV-1
infection in cultured cells, we cloned the GAG-HAM ribozyme
into a eukaryotic expression vector (Fig. 18A) and trans
fected it into HeLa CD4+ cells, a human cell line capable of
being infected by HIV-1 (Maddon et al., 1986). Polymerase
chain reaction was used to identify stable clones that
expressed the GAG-HAM ribozyme (Fig. 18B). The ribozyme
expressed in these cells is biologically active, effecting
cleavage of input target RNA in an in vitro reaction (Figure
19). These results demonstrate that despite the extended
length of the GAG-HAM ribozyme transcripts ( an ca. 400
extra nucleotides) (Fig. 18C), biologically functional GAGHAM ribozyme molecules are produced in this system. The
extra 200-300 poly adenosines added to the end of the ribo
zyme transcripts is an average amount of poly adenylation
seen with mammalian systems, and probably serves to stabil
ize the ribozyme transcripts against degradation.
HeLa CD4+ cells stably expressing GAG-HAM ribozyme
cells were challenged with HIV-1. Using a commercially
available ELISA test (Table 2), the soluble p24 antigen
level ( gag protein) at 7 days after infection was
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determined quantitatively. The secreted p24 concentration
was slightly lower for cloned transformants (0.14 ng/ml) as
compared to the pooled transformants (0.23 ng/ml). The
difference between the two transformant samples were insig
nificant when compared to the concentration from the un
transformed cells (>10 ng/ml). The greatly reduced viral p24
antigen levels were

possibly the result of decreased p24

protein production due to the cleavage of gag mRNAs.

We

have obtained data suggesting cleavage of HIV-1 gag region
RNAs in HIV-1 infected HeLa CD4+ cells expressing GAG-HAM
ribozyme. The detection method was an indirect method using
PCR analysis as described above. We reasoned that if cleav
age of HIV-1 gag RNA occurs, the amount of gag RNA contain
ing the cleavage site should be reduced as compared to the
amount of gag RNA 3' to the cleavage site.

The relative

ratio of the two amplified products quantitate the effec
tiveness of the intracellular activity of the ribozyme. Both
samples from the ribozyme expressing cells showed a greatly
reduced ratio of the amplified products (Fig. 20). To our
surprise, the amplified product representing the uncleaved
viral RNA was almost undetectable in the pooled ribozyme
expressing cells. The smaller amplified product representing
both the cleaved and uncleaved RNAs were lower in samples
from ribozyme expressing HeLa CD4+ cells as compared with a
sample from parental HeLa CD4+ cells, suggesting that the
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viral load had been greatly reduced in the ribozyme express
ing cells.

Despite these results, it remains to be deter-

mined what types of correlations can be drawn by comparing
the in vitro and the in vivo ribozyme mediated cleavage
reactions.
The presence of antisense agents in cells may have
profound effects on cell growth. One of our stably express
ing ribozyme clones was tested for possible cytotoxicity by
comparing its growth properties with the parental cell line
(Fig. 19B). No cytotoxicity was observed as determined by
short term growth and trypan blue cell exclusion (Table 2).
The lack of an obvious deleterious effect on the cells
suggests that the constitutive intracellular expression of
ribozyme may be a potentially useful therapeutic strategy
for producing a new anti-viral immunity. In our study, the
intracellularly expressed anti-HIV-1 ribozyme did not render
complete immunity to HIV-1 infection since we were able to
detect small amounts of proviral DNA in the cell population
(data not shown). Perhaps an elevation in the expression
level of the ribozyme could render a full immunity to the
cells. An inducible expression system can be employed to
increase intracellular concentration of the ribozyme only
when desired, thereby minimizing possible cytotoxic effects
on the cells. The inducible expressions of antisense RNAs
against c-fos and c-src have been obtained using the
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steroid-inducible MMTV promoter (Holt et al., 1986) and the
inducible metallothionein promoter (Amini et al., 1986),
respectively. Ribozyme expression can be increased from a
basal level to a potentially cytotoxic, but therapeutic
level, simply by the addition of exogenous inducing com
pounds to the cells. The cytotoxicity, if any, is minimized
by the on-demand expression, preventing the interference of
ribozyme activity with cellular function when ribozyme is
not needed. Further investigation of a number of parameters
affecting intracellular ribozyme expression should facilit
ate our understanding of what factors must be considered in
order to optimize the intracellular effectiveness of trans
acting ribozymes.
Yeast model for studying ribozyme.
The study of parameters affecting intracellular ribo
zyme expression and activity using yeast Saccharomvces
cerevisiae as a model system has been initiated. Since yeast
and mammalian cells share many of the cellular characteris
tics that are important to ribozyme expression and activity
such as: 1)subcellular organelles: compartmentalization of
ribozymes and/or target mRNA; 2) chromosome mechanics:
stability of chromosomal versus episomal expressions? 3)
nucleus and cytoplasm: localization of the site of ribozyme
activity?

4) the three modes of transcription using Pol I,

Pol II and Pol III? and 5) the effects of post-transcriptional processing on ribozyme activity and stability of each
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transcript. The information gathered in yeast should be
pertinent to a mammalian system. The compartmentalization of
either ribozymes or target mRNAs can be studied by sub
organelle fractionation and probing for transcripts in each
fraction. The study of chromosomal versus episomal expres
sion is facilitated in yeast by the availability of the
three yeast shuttle vector systems (Botstein and Davis,
1982). The yeast centromere plasmid (pYC) is a low-copy,
autonomously replicating, plasmid capable of proper segrega
tion. This type of plasmid carries a copy of yeast centro
mere (CEN) and autonomously replicating sequence (ARS), and
acts similar to a mini-chromosome. The second type of plas
mid is the yeast episomal plasmid (pYE), which contains the
replication origin from the yeast 2 micron plasmid. This
plasmid is capable of maintaining high-copy number and
replicates autonomously but segregates irregularly. The
third type of plasmid is the yeast integrative plasmid (pYI)
which allows integration of cloned genes into the yeast
genome by homologous recombination. Using the three types of
plasmids, information about expression levels and stability
of ribozyme and the ribozyme genes can be obtained. The
elucidation of the cellular site of ribozyme action (nuclear
or cytoplasmic) can be understood by selectively targeting
the ribozyme to those sites. The nuclear site of action can
be confirmed by targeting splice junctions and introns to
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inhibit further processing of pre-mRNA. A good cytoplasmic
target is the region adjacent to the mRNA cap site and AUG
translational initiation codon. Transcripts from RNA poly
merase II synthesis have been shown to undergo capping and
polyadenylation, presumably enhancing its stability. The
effect of post-transcriptional processing on ribozyme ac
tivity is still unclear.

In our studies, intracellularly

expressed GAG-HAM ribozyme undergoes post-transcriptionalmodification and still retains catalytic activity.

By using

transcriptional strategies which result in different types
of post-transcriptional processing, some information on the
effect of different processing events on ribozyme activity
may be elucidated.
The yeast system described here utilizes an S.
cerevisiae actin-E. coli lacZ

fusion gene as a reporter

construct. The anti-lacZ ribozyme was cloned into a yeast
expression vector under the control of the Gal 1 inducible
promotor. The expression of this ribozyme was shown to be
inducible (Fig. 24A) and the intracellularly expressed RNA
was determined to have biological activity (Fig. 24B).
However, after its synthesis and cloning, it was found that
GAL-HAM ribozyme contained a one base pair mismatch two
nucleotides 3' to the GUC cleavage site (Fig. 23). To cor
rect the mismatch, a PCR based mutagenesis procedure was
used to produce the BETA-HAM ribozyme. The in vitro
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activities of the two ribozymes were compared directly at
two temperature, 30°C and 50°C (Fig. 23). At both tempera
tures, BETA-HAM ribozyme cleaved the substrate at a greater
efficiency, approximately 3.5 x greater at 30°C but only 1.2
x greater at 50°C. The reduction in the difference of the
activities at 50°C suggested that the actual cleavage event
occurs rapidly following formation of the appropriate con
formation. The increase in activity of GAL-HAM at 50°C can
possibly be explained by the dynamics of the catalytic
center which may have different conformational forming
abilities. At the higher temperature, the constraint of the
mismatch is overcome, allowing rapid, transient formation of
the correct conformation, and subsequent cleavage of the
substrate.
Both BETA-HAM and GAL-HAM ribozymes were cloned into a
GAL1 promotor expression vector. Preliminary data (not
shown) suggests that neither ribozyme inhibited production
of the fusion protein in yeast as measured by a B-galactosidase activity assay. Several factors could contribute to
this observed lack of inhibition. These include, but are not
limited to the following: 1) the different comparmentalization of intracellular expressed ribozyme and substrate
mRNAs, 2) the stability of the expressed protein which leads
to maintenance of steady state concentrations of B-galactosidase even if the mRNA level is reduced, 3) the
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inaccessibility of the cleavage site to ribozyme due to the
binding of either the target site or ribozyme by some RNA
binding protein. These possible explanations can be tested
via experiments involving cellular fractionation and PCR
analysis to quantitate the level of mRNA.
Liposome delivery system.
The transient nature of the protection rendered by the
exogenously delivered ribozyme to cells is mainly dependent
upon the intracellular concentration of ribozyme. Two fac
tors, that can increase the intracellular concentration of
the exogenously delivered ribozyme have been explored.
First, a lipid-mediated facilitative delivery system (lipo
some)

(Knight, 1981; Ostro, 1983) was shown not only to

facilitate the uptake process but also protects the RNA
molecules from being degraded by ribonucleases for up to 40
hours in the presence of serum in the media (Fig. 21A lane
40-1). With proteins attached to the surface, liposomes can
also be constructed resulting in a "magic bullet" delivery
system with biological homing devices which can selectively
target HIV-1 infected cells, or CD4+ cells capable of HIV-1
infection. Different formulations of the lipid components
can also affect the final localization of the delivered
ribozyme within the cells. The usefulness of liposome deliv
ery systems has resulted in the limited approval by FDA for
clinical use of two liposome based pharmaceutical agents,
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AmBisome and VesScan (produced by Vestar, San Dimas, CA.)*
The use of liposomes as a ribozyme delivery system may prove
to be very beneficial but further studies are required.
Secondly, chemically synthesized ribozymes that contain
ribonucleotides only in the catalytic center, and deoxyribonucleotides throughout the rest of the molecule were tested
(Fig. 22). It is anticipated that this molecule will be more
stable in vivo, and our design is easier and less expensive
to synthesize chemically. The substitution of DNA in place
of RNA increases the potential for exploring

possibilities

of using deoxyribonucleotide analogs or attaching chemical
groups to the deoxyribonucleotide ends. The use of deoxy
ribonucleotide analogs such as nucleoside phosphorothioate
(Matsukura et al., 19887; 1989) or nucleoside methylphosphonates (Miller et al., 1979? Zaia et al., 1988) have
been shown to be more resistant to cellular degradation as
well as increasing the solubility of the oligonucleotide in
cellular membranes leading to increased cellular uptake. An
alpha conformation of the flanking DNA regions can be syn
thesized to increase the stability of the molecules (Morvan
et al., 1987; Thuong et al., 1987). The enhancement of
cellular uptake can also be achieved by the attachment of
chemical groups to the DNA ends such as the cholesterylconjugated oligonucleotides (Letsinger et al., 1989). The
attachment of reactive chemical groups to ribozymes is
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another possible route to increase the reactive nature of
the molecules. However, intercalating agents such as acri
dine (Toulme et al., 1986; Cazenave et al., 1987? Verspieren
et al., 1986) and cross-linking agents such as psoralen (Lee
et al., 1988) can lead to both specificity and cytotoxicity
problems. Since ribozymes themselves are somewhat reactive
due to the nature of their cleavage activity, attachment of
additional reactive agents to ribozymes may be counterpro
ductive.
We have explored the possible use of ribozymes as
therapeutic agents via two techniques of intracellular
delivery: 1) endogenous expression of ribozymes cloned into
a transcriptional unit and 2) exogenous delivery of per
formed ribozymes. One possible therapeutic modality for
endogenous expression of ribozyme is via a gene therapy
approach. Bone marrow transplantation has been proposed as a
means of managing HIV-1 infection (Holland et al., 1989).
One can envision that anti-HIV-1 ribozyme gene constructs
can be introduced into marrow derived stem cells prior to
transplantation.

An alternate route is infusion of pre

formed anti-HIV-1 catalytic RNAs packaged in some type of
delivery system that specifically fuses to HIV-1 infected
cells or, as a preventive measure, fuses to CD+4 cells
before any possible HIV-1 contact. A possible system that
can specifically deliver preformed ribozymes to a selective
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group of cells is a liposome based delivery system that
either incorporates recombinant CD4 receptors or recombinant
viral gpl20 proteins onto its surface. Such a delivery
system may be capable of fusing to infected cells.
Future directions:
1) The development of a yeast system that is capable of
rapid, quantitative analyses of the different parameters
that affect the intracellular expression of ribozyme and its
activities. The information gathered in a yeast system
should then be tested in a mammalian cell culture system.

2) The continued development of a liposome based delivery
system that is capable of high efficiency delivery of pre
formed ribozymes and is also capable of selectively deliver
ing ribozymes to specifically targeted cell types.

3) A thorough analysis of the effects of mutations in the
flanking base paired regions on the catalytic efficiency.
The hypermutability of the HIV-1 virus potentially can lead
to the inactivation of ribozyme activity. The determination
of the effects of mutations such as those found in GAL-HAM
ribozyme will lead to the development of ribozyme designs
and target choices which will minimize such potential inac
tivation.
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4) The development of an animal model for testing ribozyme
activity.

Two potential systems are the SCID-hu mice (Nami-

kawa et al., 1988) and the human/immune-deficient (HID) mice
(Kamel-Reid and Dick, 1988) which can be produced with
hematopoietic stem cells that contain ribozymes.

5) The continued exploration of chemically synthesized DNARNA hybrid catalytic molecules for their intracellular
activity and

testing of chemical modifications of such

molecules for possible enhancement of intracellular stabil
ity and cellular uptake.
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